Cover Page for Protocol 
Sponsor name:  'LFHUQD3KDUPDFHXWLFDOV , Inc. 
NCT number 1&7
Sponsor trial ID: '&5$8'
Official title of study: $3KDVHE'RXEOHEOLQG3ODFHERFRQWUROOHG5HSHDWGRVH 
6DIHW\ 7ROHUDELOLW\ 3KDUPDFRNLQHWLF DQG 3KDUPDFRG\QDPLF
6WXG\RI'&5$8'LQ+HDOWK\9ROXQWHHUV    
Document date*: -DQXDU\
*Document date refers to the date on which the document was most recently updated.
Dicerna Protocol DCR-AUD-102 Version 2.0, 17-Jan-2023 
 Page 4 PROTOCOL AMENDMENT SUMMARY OF CHANGES 
 
DOCUMENT HISTORY 
Document Date 
Amendment 1 17-Jan-2023 
Original Protocol 06-Dec-2022 
 
Amendment 1 (17-Jan-2023) Overall Rationale for the Amendment: 
The protocol was amended in response to que ries from the US Food and Drug Administration. 
Additional updates and clar ifications were also included. A su mmary of all changes follows in 
the table below.  
Description of Change Brief Rationale Section # and Name 
[INVESTIGATOR_117505], following an SAE, 
additional EIAs will not be 
performed if the SAE may have been 
related to study intervention and that 
repeat EIAs may pose a recurrent risk 
to the participant. To enhance participant safety and 
allow for PI [INVESTIGATOR_800685]. 7.3.1  Serious Adverse Event 
Decrease from 3 to 2 the number of 
participants experiencing a Grade 3 CTCAE event that would trigger a study stoppi[INVESTIGATOR_1877]. To enhance participant safety.  7.4. Study Stoppi[INVESTIGATOR_800686] 24-hour postdose PK 
blood sample is collected (increases 
in-clinic admission by [CONTACT_800714]). 
Also results in change of timing for distribution of alcohol use symptom diary. To simplify clinical operations and 
reduce the likelihood of missed 
sample collection. 1.3. Schedule of Activities 
Changed pre-admission alcohol 
testing from urine to breath. Breath-alcohol testing provides a 
more accurate assessment of recent 
alcohol intake than does urine 
testing. 1.3. Schedule of Activities 
5.3. Lifestyle Considerations 
8.6.1.  Ethanol Interaction 
Assessments 
10.2.  Clinical Laboratory Tests 
Added that a positive urine drug 
VFUHHQRQ'D\√≠ (in addition to at 
Screening) will result in study exclusion. To ensure that participants are not 
users of illicit drugs. 1.3. Schedule of Activities 
5.2. Exclusion Criteria 
Updated text in Exclusion Criterion 
#3 (history of suicidal ideation or 
behavior). To provide clarification on the 
timeframe during which positive 
answers in the C-SSRS would result 
in study exclusion. 5.2. Exclusion Criteria 
Dicerna Protocol DCR-AUD-102 Version 2.0, 17-Jan-2023 
 Page 5 Description of Change Brief Rationale Section # and Name 
[CONTACT_800743]-AUD may also be analyzed To provide for a more complete PK 
profile of DCR-AUD 8.5 Pharmacokinetics 
Changed sampling times for blood 
draws for ADA detection from 
Days 29 and 57 to Days 42 and 70. To provide for ADA sample 
collection 14 days after each dose 
administration. 1.3. Schedule of Activities 
Changed timing of ALDH2  
genotypi[INVESTIGATOR_800687] √≠ To allow that only eligible 
participants undergo genotypi[INVESTIGATOR_007]. 1.3. Schedule of Activities 
  
Dicerna Protocol DCR-AUD-[ADDRESS_1105237] INFORMATION ............3  
PROTOCOL AMENDMENT SUMMARY OF CHANGES ..........................................................4  
1. PROTOCOL SUMMARY ..........................................................................................11  
1.1. Synopsis ...................................................................................................................... 11 
1.1.1.  Rationale ..................................................................................................................... 11 
1.1.2.  Objectives and Endpoints ...........................................................................................12  
1.1.3.  Overall Design ............................................................................................................12  
1.2. Overall Study Schema ................................................................................................14  
1.3. Schedule of Activities (SoA) ......................................................................................15  
2. INTRODUCTION ......................................................................................................21  
2.1. Study Rationale ...........................................................................................................21  
2.1.1.  Overview of Alcohol  Use Disorder ............................................................................21  
2.1.2.  Nonclinical Overvi ew of DCR-AUD .........................................................................22  
2.2. Benefit/Risk Assessment ............................................................................................23  
2.2.1.  Risks Related to DCR-AUD Mechanism of Action ...................................................23  
2.2.2.  Risk Assessment .........................................................................................................25  
2.2.3.  Benefit Assessment .....................................................................................................26  
2.2.4.  Overall Benefit:Risk Conclusion ................................................................................26  
3. OBJECTIVES AND ENDPOINTS ............................................................................27  
4. STUDY DESIGN .......................................................................................................28  
4.1. Overall Design ............................................................................................................28  
4.2. Scientific Ra tionale for Study Design ........................................................................28  
4.3. Justification for Dose ..................................................................................................29  
4.4. End of Study Definition ..............................................................................................29  
5. STUDY POPULATION .............................................................................................30  
5.1. Inclusion Criteria ........................................................................................................30  
5.2. Exclusion Criteria .......................................................................................................31  
5.3. Lifestyle Considerations .............................................................................................33  
5.4. Screen Failures ............................................................................................................34  
Dicerna Protocol DCR-AUD-102 Version 2.0, 17-Jan-2023 
 Page 7 6. STUDY INTERVENTION ........................................................................................35  
6.1. Study Intervention(s) Administered ...........................................................................35  
6.2. Preparation/Handling/Storage/Accountability ............................................................35  
6.2.1.  Handling and Accountability ......................................................................................35  
6.2.2.  Storage ....................................................................................................................... .36 
6.2.3.  Preparation and Administration ..................................................................................36  
6.3. Measures to Minimize Bias: Randomization and Blinding ........................................36  
6.4. Study Intervention Compliance ..................................................................................37  
6.5. Dose Modification ......................................................................................................37  
6.6. Continued Access to Study Intervention after the End of the Study. .........................37  
6.7. Concomitant Therapy .................................................................................................37  
6.7.1.  Rescue Medicine .........................................................................................................38  
7. DISCONTINUATION OF STUDY INTERVENTION AND 
PARTICIPANT DISCONTINUATION/WITHDRAWAL .......................................38  
7.1. Participant Discontinuation/W ithdrawal from the Study ...........................................[ADDRESS_1105238] to Follow Up .......................................................................................................38  
7.3. Individual Participant Stoppi[INVESTIGATOR_1869] ........................................................................39  
7.3.1.  Serious Adverse Event ................................................................................................39  
7.3.2.  Abnormal Liver Function Tests ..................................................................................39  
7.3.3.  Electrocardiogram Findings ........................................................................................39  
7.3.4.  Significant Negative Reaction to Alcohol Ingestion ..................................................39  
7.4. Study Stoppi[INVESTIGATOR_1869] .................................................................................................40  
8. STUDY ASSESSMENTS AND PROCEDURES ......................................................40  
8.1. Efficacy Assessments .................................................................................................40  
8.1.1.  Alcohol Consumption via Timeline Follow Back ......................................................41  
8.1.2.  Blood Phosphatidylethanol Levels .............................................................................41  
8.2. Safety Assessments .....................................................................................................41  
8.2.1.  Screening Tests ...........................................................................................................42  
[IP_ADDRESS].  Mini-International Neurop sychiatric Interview ..........................................................42  
[IP_ADDRESS].  Laboratory Tests to Determine Eligibility ..................................................................42  
8.2.2.  Physical Examinations ................................................................................................42  
8.2.3.  Vital Signs ..................................................................................................................4 2 
8.2.4.  Electrocardiograms .....................................................................................................43  
Dicerna Protocol DCR-AUD-102 Version 2.0, 17-Jan-2023 
 Page 8 8.2.5.  Suicidal Ideation and Behavior Risk Monitoring .......................................................43  
[IP_ADDRESS].  Columbia-Suicide Seve rity Rating Scale ....................................................................43  
8.2.6.  Clinical Safety Labor atory Assessments ....................................................................44  
8.2.7.  Pregnancy Testing ......................................................................................................44  
8.3. Adverse Events, Serious Adverse Even ts, and Other Safety Reporting .....................44  
8.3.1.  Time Period and Frequency for Coll ecting Adverse Event Information ....................45  
8.3.2.  Method of Detecti ng AEs and SAEs ..........................................................................45  
8.3.3.  Follow-up of AEs and SAEs .......................................................................................45  
8.3.4.  Regulatory Reporting Requi rements for SAEs ...........................................................45  
8.3.5.  Pregnancy ...................................................................................................................46  
8.4. Treatment of Overdose ...............................................................................................46  
8.5. Pharmacokinetics ........................................................................................................46  
8.6. Pharmacodynamics .....................................................................................................47  
8.6.1.  Ethanol Interaction Assessments ................................................................................47  
[IP_ADDRESS].  EIA Blood Biomarkers ...............................................................................................48  
[IP_ADDRESS].  EIA Physiologic Signs and Symptoms .......................................................................48  
[IP_ADDRESS].  Stoppi[INVESTIGATOR_47934] ..........................................................................................48  
[IP_ADDRESS].  Follow-up of Participants Who Continue to have Positive Ethanol Reaction 
Symptoms at Day 168 (Conditional Follow-up) ........................................................49  
8.6.2.  Presence of Physiologic Symptoms Asso ciated with Consumption of Ethanol 
Outside of EIAs ..........................................................................................................49  
8.7. Genetics ...................................................................................................................... 49 
8.8. Immunogenicity Assessments ....................................................................................49  
8.9. Health Economics .......................................................................................................50  
9. STATISTICAL CONSIDERATIONS .......................................................................50  
9.1. Statistical Hypotheses .................................................................................................50  
9.2. Sample Size Determination ........................................................................................50  
9.3. Populations for Analyses ............................................................................................51  
9.4. Statistical Analyses .....................................................................................................51  
9.4.1.  General Considerations ...............................................................................................51  
9.4.2.  Primary Endpoint(s) ....................................................................................................52  
9.4.3.  Secondary Endpoints ..................................................................................................52  
[IP_ADDRESS].  EIA Composite Score .................................................................................................52  
Dicerna Protocol DCR-AUD-102 Version 2.0, 17-Jan-2023 
 Page 9 [IP_ADDRESS].  Blood Biomarkers .......................................................................................................53  
[IP_ADDRESS].  Pharmacokinetics ........................................................................................................53  
9.4.4.  Exploratory Endpoint(s) .............................................................................................53  
9.5. Interim Analysis ..........................................................................................................53  
9.6. Safety Review Committee and Data  Safety Monitoring Committee..........................53  
10. SUPPORTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS ..................................................................................................56  
10.1.  Regulatory, Ethical, and Study Ov ersight Considerations .........................................56  
10.1.1.  Regulatory and Ethical Considerations ......................................................................56  
10.1.2.  Financial Disclosure ...................................................................................................56  
10.1.3.  Informed Consent Process ..........................................................................................56  
10.1.4.  Data Protection ...........................................................................................................57  
10.1.5.  Committees Structure .................................................................................................57  
[IP_ADDRESS].  Safety Review Committee ..........................................................................................57  
[IP_ADDRESS].  Data Safety Monitoring Committee ............................................................................57  
10.1.6.  Dissemination of Clinical Study Data ........................................................................58  
10.1.7.  Data Quality Assurance ..............................................................................................58  
10.1.8.  Study and Site Start and Closure ................................................................................59  
10.1.9.  Publication Policy .......................................................................................................60  
10.2.  Clinical Laboratory Tests ...........................................................................................60  
10.3.  Adverse Events: Definitions and Pr ocedures for Recording, Evaluating, 
Follow-up, and Reporting ...........................................................................................[ADDRESS_1105239] .......................................................63  
10.3.4.  Recording and Follow-up of AEs and/or SAEs ..........................................................64  
[IP_ADDRESS].  AE and SAE Recording ..............................................................................................64  
[IP_ADDRESS].  Assessment of Intensity ..............................................................................................65  
[IP_ADDRESS].  Assessment of Causality .............................................................................................65  
[IP_ADDRESS].  Follow-up of AEs and SAEs .......................................................................................66  
10.3.5.  Reporting of SAEs ......................................................................................................66  
10.4.  Contraceptive Guidance and Collecti on of Pregnancy Information ...........................66  
10.4.1.  Definitions ..................................................................................................................6 6 
Dicerna Protocol DCR-AUD-102 Version 2.0, 17-Jan-2023 
 Page 10 10.4.2.  Contraception Guidance .............................................................................................67  
10.4.3.  Collection of Pregna ncy Information .........................................................................68  
[IP_ADDRESS].  Male Participants with Partners Who Become Pregnant ............................................68  
[IP_ADDRESS].  Participants Who B ecome Pregnant ...........................................................................69  
10.5.  Genetics ...................................................................................................................... 69 
10.6.  Liver Safety: Suggested Actions  and Follow-up Assessments ...................................70  
10.7.  Abbreviations ..............................................................................................................72  
10.8.  Protocol Amendment History .....................................................................................76  
10.9.  Investigator Signature [CONTACT_3490] ........................................................................................77  
11. REFERENCES ...........................................................................................................78  
 
Table of Tables 
Table 1:  Schedule of Activities ‚Äì Screening, Dosing, EOS, and CFU Visits (see 
Table 2 for non-dosing visits) .....................................................................................15  
Table 2:  Schedule of Activities ‚Äì Non-dosing Vi sits (see Table 1 for Screening, 
Dosing, and EOS Visits) .............................................................................................18  
Table 3:  Schedule of Activities - 4-Hour Et hanol Interactio n Assessments .............................20  
Table 4:  Study Intervention Administered ................................................................................35  
Table 5:  Minimal Timing of the Safety Review Committee Da ta Reviews .............................55  
Table 6:  Protocol-Required Safety Laboratory Assessments ...................................................61  
Table 7:  Grading of Injection Site Reactions, CTCAE v 5.0 ....................................................64  
Table 8:  Highly Effective Contraceptive Methods ...................................................................68  
 
Table of Figures 
Figure 1:  Study Schematic fo r DCR-AUD-102 .........................................................................14  
 
Dicerna Protocol DCR-AUD-102 Version 2.0, 17-Jan-2023 
 Page 11 1. PROTOCOL SUMMARY 
1.1. Synopsis 
Protocol Title: A Phase 1b, Double-blind, Placebo-controlled, Repeat-dose, Safety, 
Tolerability, Pharmacokinetic, and Phar macodynamic Study of DCR-AUD in Healthy 
Volunteers  
Short Title:  Phase 1b Repeat Dose Study of DCR-AUD in Healthy Volunteers  
1.1.1.  Rationale 
DCR-AUD is being developed for the treatment of al cohol use disorder (AUD) in adults using an 
RNA interference (RNAi) technol ogy platform. DCR-A1203, the drug substance of DCR-AUD, 
is a synthetic double-stranded (annealed duplex ) RNA oligonucleotide conjugated to GalNAc 
ligands that enable subcutaneous delivery of  stable, highly specific, and long-acting knockdown 
of mRNA in the liver via hepa tic GalNAc carbohydrate receptors. The target of DCR-AUD is 
aldehyde dehydrogenase 2 (ALDH2), one of the primary enzymes required for alcohol 
metabolism. Alcohol metabolism occu rs predominantly in the liver via a 2-step process in which 
alcohol is first converted to acetaldehyde via alcohol dehydrogenase  and then to acetic acid by 
[CONTACT_800715]2. ALDH2 enzyme inhibition can resu lt in unpleasant symptoms after alcohol 
consumption such as flushing, headache, lightheadedness, palpi[INVESTIGATOR_814], nausea, and vomiting, as 
a result of unmetabolized acetaldehyde accu mulation. Unpleasant reactions to alcohol 
consumption in humans with naturally occurring ALDH2  mutations are thought to be protective 
against AUD and account for its low prevalen ce in individuals who are heterozygous or 
homozygous for ALDH2  allele mutations causing slower  metabolism of acetaldehyde. The 
magnitude and duration of acet aldehyde accumulation is proportional to both the degree of 
ALDH2 enzyme inhibition (e.g., partial vs to tal) and the amount of  alcohol consumed. 
DCR-AUD is designed to selectively reduce ALDH2  mRNA and ALDH2 activity in the liver, 
and thereby [CONTACT_47973]. In cynomolgus monkeys, a single SC dose of 3 mg/kg DCR-AUD resulte d in reduction of 
ALDH2 mRNA expression in liver up to [ADDRESS_1105240] (resulting 
from cumulative ALDH2  mRNA knock down) can be observe d during Ethanol Interaction 
Assessments (EIA) in a population of social drinkers after repeat doses of DCR-AUD.  
 
Dicerna Protocol DCR-AUD-102 Version 2.0, 17-Jan-2023 
 Page 13 Intervention Gro ups and Duration: 
Participants will be randomized [ADDRESS_1105241] injection of study intervention.  
Study Population Key Criteria: 
x Overtly healthy men and women aged 21 to 65 years. 
x No diagnosis of AUD within the preceding 12 months per Diagnostic and Statistical 
Manual of Mental Disorders (DSM-5). 
x Social drinkers who consume, on average, [ADDRESS_1105242] by [CONTACT_800716]. 
x No history of substance use disorder (SUD) or illicit drug use (excluding cannabis) 
within the preceding 12 months. 
x No history of alcohol withdrawal sympto ms including delirium tremens or alcohol-
related seizures. 
Treatment Blinding:  
Participants and site study sta ff will be blinded to the rando mization. Some members of the 
Sponsor team will be unblinded. Co mplete details will be  presented in the Study Blinding Plan.  
Dicerna Protocol DCR-AUD-102 Version 2.0, 17-Jan-2023 
 Page 14 1.2. Overall Study Schema 
Figure 1: Study Schematic for DCR-AUD-102 
 
 
 

Dicerna Protocol DCR-AUD-102 Version 2.0, 17-Jan-2023 
 Page 15 1.3. Schedule of Activities (SoA) 
Table 1: Schedule of Activities ‚Äì Screening, Dosing, EOS, and CFU Visits (see Table 2  for non-dosing visits) 
 Screen Dosing Visits EOS/ET a CFUb 
Study Week  ‚Äî 4 8 24 28 
Study Day √≠WR√≠  √≠ 1 2 4 28 29 30 32 56 57 58 168 169 197 
Window (days) c   ‚Äì ‚Äì ‚Äì ‚Äì ‚Äì ¬±2 ‚Äì ‚Äì ‚Äì ¬±2 ‚Äì ‚Äì ¬±7 ¬±7 
Procedure/Assessment   Pre Post    Pre Post    Pre Post     
I n f o r m e d  c o n s e n t   X                   
Inclusion/exclusion criteria X X                 
Demographic characteristics X                  
G e n e r a l  m e d i c a l  h i s t o r y  X                   
M e d i c a t i o n  h i s t o r y  X                   
Psychological history X                  
Urine drug testing d X                   
Screening laboratory testing e X                   
ALDH2  genotypi[INVESTIGATOR_007] f  X                  
M I N I  S c r e e n  X                   
C-SSRS g X X     X     X    X   
Alcohol TLFB h X X     X     X    X  X 
Pregnancy test i X X     X     X    X  X 
SARS-CoV-[ADDRESS_1105243] j  X     X     X    X   
Drug/alcohol screen k  X     X     X    X   
Clinic site admission l  X     X     X    X   
Dicerna Protocol DCR-AUD-102 Version 2.0, 17-Jan-2023 
 Page 16 Table 1: Schedule of Activities ‚Äì Screening, Dosing, EOS, and CFU Visits (see Table 2  for non-dosing visits) (Continued) 
 Screen Dosing Visits EOS/ET a CFUb 
Study Week  ‚Äî 4 8 24 28 
Study Day √≠WR√≠  √≠ 1 2 4 28 29 30 32 56 57 58 168 169 197 
Window (days) c   ‚Äì ‚Äì ‚Äì ‚Äì ‚Äì ¬±2 ‚Äì ‚Äì ‚Äì ¬±2 ‚Äì ‚Äì ¬±7 ¬±7 
Procedure/Assessment   Pre Post    Pre Post    Pre Post     
Clinic site discharge m     X     X     X  X  
EIA n  X     X     X    X   
R a n d o m i z e    X                 
Administer study intervention   X    X    X     
12-lead ECG o X  X X    X X    X X   X  
Vital signs X p  X X q    X  X q    X X q   X  
Physical examination r X X     X     X    X   
Blood sample for PEth s  X           X     X    
Hematology, chemistry, UA t  X     X     X    X   
Coagulation panel u  X     X     X    X   
Complement panel v   X X X        X X X    
Blood sample for ADA w   X              X    
Blood sample for PK x   X X X X  X X X X  X X X X   
Alcohol use symptom diary y  X   X  X   X  X   X X  X 
Record AEs & SAEs z X X X X X X X X X X X X X X X X X X 
Record concomitant meds  X X X X X X X X X X X X X X X X X 
Abbreviations: ADA=antidrug antibody; AE=adverse event; ALDH2 =aldehyde dehydrogenase 2 gene; CBC=complete blood count; CFU=conditional follow-up visit; 
C-SSRS=Columbia-Suicide Severity Rating Scale; ECG=electrocardiogram; EIA=ethanol interaction assessment; EOS=end of study; ET= early termination; 
FSH=follicle-stimulating hormone; HbA1c=hemogl obin A1c; ICF=informed consent form; MINI =Mini-International Neuropsychiatric Int erview; PEth=phosphatidylethanol; 
PK=pharmacokinetic; RBC=red blood cell; SAE=serious adverse event; SARS-CoV-2=severe acute respi[INVESTIGATOR_6507] 2; SIB=suicidal ideation or behavior; 
TLFB=Timeline Follow Back; UA=urinalysis  
a At the time of discontinuation for the study, an early termination (ET) visit should be conducted, if possible. 
Dicerna Protocol DCR-AUD-102 Version 2.0, 17-Jan-2023 
 Page 17 b Participants with significant symptoms at  the Day 168 EIA will be followed for an ad ditional 4 weeks at the discretion of the I nvestigator. 
c Visits without a specified window are to be conducted relative to the associated scheduled visit. For example, Day 28 will alw ays be the day prior to the Day 29 visit, regardless 
of where Day 29 falls within the ¬± 2-day visit window 
d Screening tests positive for cannabis are not exclusionary. 
e To include hematology (CBC with differential and RBC indices), clinical chemistry, coagulation panel, urinalysis, viral serolo gy, HbA 1c, and FSH (as indicated). See 
Section 10.[ADDRESS_1105244] of parameters. 
f Baseline genetic testing for ALDH2  mutations. Participation is optional; participants who do not wish to undergo genotypi[INVESTIGATOR_800688]. 
g The Baseline version will be administered at Screening and at subsequent visits the ‚ÄúC-SSRS Since Last Visit‚Äù version will be administered. Participants who exhibit signs of 
Suicidal Ideation or Behavior (SIB) should undergo a risk assessment. All factors contributing to SIB should be evaluated and c onsideration should be given to discontinuation 
of study intervention.  
h TLFB will be completed for the 2-week period that precedes each study visit, including Screening. 
i Pregnancy testing required only in female participants. If a ur ine pregnancy test is positive, confirm with serum pregnancy te st. Local laboratory may be used. Female 
participants must have a negative pregnancy test prior to overnight admission. 
j Testing to be performed at the site upon admission. Participants with a positive SA RS-CoV-[ADDRESS_1105245] will not be admitted to clini c and will not receive study intervention or undergo 
EIA. Other assessments not requiring clinic admission (i.e., safety assessments) will be performed. Testing will be performed p er site standard processes. 
k Study participants are to refrain from drinking alcohol and using cannabis for [ADDRESS_1105246] been completed. A total of 10  EIAs will be conducted. The timing of assessments 
and ethanol administration are detailed in Table 3 .  
o On dosing days, ECGs will be conducted approximately 30 minute s predose and 15-to-30 minutes postdose. If multiple assessments  are due, the order of assessment should be 
ECG, vitals, PK, and then other assessments; with PK sample collection occurring at th e nominal time. At Screening and EOS, one  ECG will be performed. Screening ECGs 
may be repeated one time for determination of eligibility. 
p Blood pressure, if out of range at Screening, may be  repeated one time for determination of eligibility. 
q Blood pressure and pulse rate to be recorded 15 (¬±5) minutes postdose. 
r Height will be measured and recorded at Screening. Weight will be measured and recorded at every visit. 
s Sample to be collected prior to ethanol administration.  
t Hematology to include complete blood count with differential and RBC indices. See Section 10.[ADDRESS_1105247] of parameters. 
v Blood samples for complement testing to be collected predose and 2, 8, and 24 hours postdose on Day 1 and Day 57. 
w Blood sample for ADA testing to be drawn at same time as predose PK sample on Day 1. 
x Plasma samples for PK analysis to be collected predose and at 1, 2, 4, 6, 8, 24, and 72 hours postdose (exception: no 72-hour P K sample is required at Day 57). A single sample 
will be collected on Day 168. If multiple assessments are due, th e order of testing should be EC G, vitals, PK, and then other a ssessments, with the PK sampling performed 
preferably at the nominal time point. A ¬±15-minute window will be  allowed for collections at 1, 2, 4, 6, and 8 hours postdose. A ¬±30-minute window will be allowed for 
collection at 24 hours postdose. A ¬± 60-minute window will be allowed for collection at [ADDRESS_1105248] to 
follow-up.  
Dicerna Protocol DCR-AUD-102 Version 2.0, 17-Jan-2023 
 Page 18 Table 2: Schedule of Activities ‚Äì Non-dosing Visits (see  Table 1 for Screening, Dosing, and EOS Visits) 
Week 2 6 10 12 16 20 
Study Day 14 15 42 43 70 71 84 85 112 113 140 141 
Visit Window (days) a ‚Äì ¬±2 ‚Äì ¬±2 ‚Äì ¬±3 ‚Äì ¬±5 ‚Äì ¬±7 ‚Äì ¬±7 
Procedure/Assessment  
Drug/alcohol screen b c X  X  X  X  X  X  
Pregnancy test d X  X  X  X  X  X  
SARS-CoV-[ADDRESS_1105249] concomitant meds  X X X X X X X X X X X X 
Clinical site discharge p  X  X  X  X  X  X 
Abbreviations: ADA=antidrug antibody; AE=adver se event; C-SSRS=Columbia-Suicide Severity Rating Scale; EIA=ethanol interaction assessment; 
PEth=phosphatidylethanol; PK=pharmacokinetics; SAE=serious adverse event; SARS-CoV-2=severe acute respi[INVESTIGATOR_179893] 2; SIB=suicidal ideation or 
behavior; TLFB=Timeline Follow Back; UA=urinalysis  
Dicerna Protocol DCR-AUD-102 Version 2.0, 17-Jan-2023 
 Page 19 a Visits without a specified window are to be conducted relative to the associated scheduled visit. For example, Day 14 will alw ays be the day prior to the Day 15 
visit, regardless of where Day 15 falls within the ¬± 2-day visit window. 
b Study participants are to refrain from drin king alcohol and using cannabis for [ADDRESS_1105250] will not be admitted to clinic and will not undergo EIA. Other assessments not requiring clinic admission (i.e., s afety assessments) should be 
performed. 
c Other assessments not requiring clinic admission (i .e., safety assessments) should be performed. 
d Pregnancy testing required only in female participants. If a urine pregnancy test is positive, confirm with serum pregnancy te st. Local laboratory may be used. 
Female participants must have a negative pr egnancy test prior to overnight admission. 
e Participants with a po sitive SARS-CoV-[ADDRESS_1105251] be fasting for at leas t 3 hours prior to admission to the clinic. 
g Weight will be measured and recorded at each visit. 
h The ‚ÄúC-SSRS Since Last Visit‚Äù version will be administered. Pa rticipants who exhibit signs of SIB should undergo a risk assess ment.  
i Hematology to include complete blood count.  
j See Section 10.[ADDRESS_1105252] to follow-up.  
p Participants will be discharged in the morning when the PI [INVESTIGATOR_800689]. 
 
Dicerna Protocol DCR-AUD-102 Version 2.0, 17-Jan-2023 
 Page 20 Table 3: Schedule of Activities - 4-Hour Ethanol Interaction Assessments  
 Pre-EIA EIA Test Period 
Time (minutes) -50 -20 0 a 20 30 40 60 90 120 150 180 210 240 
Window (minutes)   - ¬±5 ¬±5 ¬±5 ¬±10 ¬±10 ¬±10 ¬±10 ¬±10 ¬±10 ¬±10 
Procedure:              
Standard meal b X             
Venous catheter placement c  X             
12-lead ECG d   X    X      X 
Vital signs d e    X X  X X X X  X X X 
Plasma biomarker sample d f   X  X  X X X  X  X 
Questionnaire of 6 EIA symptoms d g   X  X  X d  X  X   
Ethanol consumption h   X X  X X       
EIA AEs i   X X  X X X X X X X X 
Abbreviations: AE=adverse event; ECG=electrocardiogram; EIA=ethanol interaction assessment; PK=pharmacokinetics  
a ‚ÄúTime 0‚Äù is immediately before the first sip of ethanol is cons umed. All Time [ADDRESS_1105253] for PK sample collections. 
d If multiple assessments are due at the same timepoint, the order of assessments should be ECG, vitals, blood draw, then any o ther assessments. The 60-minute symptom 
assessment should be conducted before the start of the 4th drink. 
e To include pulse rate and blood pressure. 
f Blood samples will be collected via venous access de vice. To include acetaldehy de, acetate, and ethanol. 
g Participants will be questioned by [CONTACT_800717] 6 sy mptoms (flushing, headache, lightheadedness, palpi[INVESTIGATOR_814], naus ea, and vomiting) associated with increased blood 
acetaldehyde levels. 
h Ethanol will be consumed in 4 aliquots over an 80-minute period (20 minutes for each aliquot). Time windows do not apply to e thanol consumption. The ethanol will be mixed 
in a liquid that has no other alcohol, no caffeine, and is low in sugar. The dose of ethanol will be 0.8 g/kg (to a maximum of 56 g) for men and 0.68 g/kg (to a maximum of 
48 g) for women. See Section [IP_ADDRESS]  of the protocol for ethanol administration stoppi[INVESTIGATOR_004]. 
i AEs associated with administration of ethanol will include events spontaneously reported by [CONTACT_800718] (symptoms elicited under direct 
questioning [footnote g] are not considered AEs).   
 
Dicerna Protocol DCR-AUD-102 Version 2.0, 17-Jan-2023 
 Page 21 2. INTRODUCTION 
2.1. Study Rationale 
DCR-AUD is being developed for the treatment of AUD in adults using an RNAi technology 
platform. DCR-A1203, the drug substance of DCR-AUD, is a synthetic double-stranded 
(annealed duplex) RNA oligonucleotide conjugated to GalNAc ligands that enable specific 
hepatic access and uptake after subcutaneous (S C) administration. Once in side the hepatocyte, 
the antisense sequence of DCR-AUD is designe d to target and reduce the expression of 
ALDH2 mRNA in the liver. 
The target of DCR-AUD is ALDH2, one of the primary enzymes required for alcohol 
metabolism. Alcohol metabolism occu rs predominantly in the liver via a 2-step process in which 
alcohol is first converted to acetaldehyde via alcohol dehydrogenase  and then to acetic acid by 
[CONTACT_800715]2. DCR-AUD is designed to selectively reduce ALDH2  mRNA and ALDH2 activity in the 
liver, and thereby [CONTACT_800719]. 
ALDH2 enzyme inhibition can result in unpleasant symptoms after alcohol consumption such as 
flushing, headache, lightheadedness, palpi[INVESTIGATOR_164828], nausea, and vomiting as a result of 
unmetabolized acetaldehyde ac cumulation. Unpleasant reactions  to alcohol consumption in 
humans with naturally occurring ALDH2  mutations are thought to be protective against AUD 
and account for its low prevalence in indivi duals who are heterozygous or homozygous for 
ALDH2  allele mutations. The ma gnitude and duration of acetaldehyde accumulation is 
proportional to both the degree of ALDH2 enzyme  inhibition (e.g., partia l vs total) and the 
amount of alcohol consumed. 
Interim results of the ongoing Study DCR-AUD-[ADDRESS_1105254] shown DCR-AUD to be safe and well tolerated at doses ranging from 80 to 
960 mg, but no PD effects (sufficient elevation of plasma acetaldehyde levels or clinical 
symptoms) have been observed.  
The aims of this repeat-dose study are to charac terize the safety and tole rability and PK profiles 
of DCR-AUD when administered monthly, and to  determine if a PD effect (resulting from 
cumulative ALDH2  mRNA knock down) can be observed dur ing EIAs in a population of social 
drinkers after repeat doses of DCR-AUD.  
2.1.1.  Overview of Alcohol Use Disorder 
Alcohol use disorder is a chronic condition char acterized by [CONTACT_47980], loss of 
control over alcohol use, and a negative emoti onal state when not using alcohol. A range of 
medical, psychological, social, economic, and pe rsonal problems are associated with AUD. 
'LDJQRVLVLVGHILQHGDVPHHWLQJ¬ï  2 of 11 criteria in the Diagnos tic and Statistic al Manual of 
Mental Disorders-5 (DSM 5) during the same  12-month period. A survey of over 36,000 adults 
found AUD had a 12-month prevalence of 13.9% adults in the US in 2013 ( Grant et al., 2015 ). 
AUD often goes untreated, possibly due to the lack of adequate treatment options. It is estimated 
that < 10% of US adults with AUD seek help or  treatment, and that simila rly low percentages of 
those treated receive pharmacotherapy ( Grant et al., 2015;  SAMHSA, 2014 ; Litten et al., 2014;  
Han et al., 2015 ; Knudsen et al., 2011 ).  
Dicerna Protocol DCR-AUD-102 Version 2.0, 17-Jan-2023 
 Page 22 There are 3 FDA-approved medications for AUD: disulfiram, oral and l ong-acting injectable 
naltrexone, and acamprosate. Ho wever, many individuals show limited or no response to these 
drugs, with poor compliance a factor ( EMA, 2010 ; Gastfriend, 2014 ; Chick et al., 1992 ; 
J√∏rgensen et al., 2011 ; Bryson et al., 2011 ). Thus, there remains an unmet need for an effective 
AUD treatment. 
2.1.2.  Nonclinical Overview of DCR-AUD 
The pharmacology of DCR-A1203 was characterized in in vivo studies in mice and monkeys to 
demonstrate the ability to reduce levels of the hepatic ALDH2  mRNA. The potential for off-
target gene silencing was assessed using in silico evaluation of the human transcriptome. The 
sequence is conserved in mouse, monkey, and hu man, but not rabbit. Therefore, DCR-A1203 is 
active in both general toxicology species eval uated, mouse and monkey. In addition, a stand-
alone comprehensive safety pharmacology st udy in cynomolgus monkeys was conducted.  
Overall, the data support the hypothesis that DCR-AUD has potential to yield meaningful and 
robust clinical responses across the AUD pa tient population based upon the following:  
x A single SC dose of up to 100 mg/kg in mice resulted in a dose-depe ndent decrease in 
Aldh2  mRNA expression in liver, persistent for 14 days postdose, followed by [CONTACT_2715]-
dependent recovery. 
x Following a single 3 mg/kg SC dose of DCR-A1203, liver ALDH2 mRNA expression 
levels were reduced by > 75% in cynomolgus  monkeys, with the nadir at 28 days 
postdose, and > 50% reduction in ALDH2 mRNA expression up to 112 days postdose. 
x Repeat SC administration of DCR-A1203 at  30 to 300 mg/kg resulted in significant 
reduction of hepatic Aldh2  mRNA in mice (> 97%) and hepatic ALDH2  in monkeys 
(> 86%) at all dose levels evaluated. 
x Based on in silico  analysis, potential off-target co mplementarities with [ADDRESS_1105255] been conducted at doses up to 300 mg/kg for up 
to 6 months in mice and 9 months in monke ys. DCR-A1203 has been evaluated for potential 
genotoxicity in a bacterial reverse mutation assa y and in vitro and in vivo micronucleus studies. 
In addition, preliminary reproductiv e toxicity studies were conducted in mice and rabbits.  
x DCR-A1203 administration had no adverse e ffects on cardiovascular, respi[INVESTIGATOR_696], or 
central nervous system function in consci ous, radiotelemetry- implanted cynomolgus 
monkeys following a single SC injection of up to 300 mg/kg. 
x The administration of DCR-A1203 in repeat-dos e studies for up to 6 months in mice and 
9 months in monkeys resulted in no D CR-A1203-related, adverse findings. The NOAEL 
in the mouse and monkey repeat-dose toxicity  studies was considered to be 300 mg/kg, 
the highest dose level administered.  
Dicerna Protocol DCR-AUD-102 Version 2.0, 17-Jan-2023 
 Page 23 x In a preliminary embryofetal development (E FD) study in mice with daily SC dosing, no 
DCR-A1203-related toxicity wa s observed at dose levels up to 1000 mg/kg (highest dose 
administered). In a preliminary EFD study in rabbits with daily SC dosing (dose levels 
from 2 to 50 mg/kg), maternal toxicity (lower body weight gains and lower food 
consumption) in dams and embryofetal eff ects (higher post implantation loss and lower 
mean fetal weights) were observed at a ll DCR-A1203 dose levels. The human relevance 
of these contradictory observations in mice and rabbits is unclear, as DCR-A1203 is not 
pharmacologically active in rabbits and no su ch observations were noted in the EFD 
study in the pharmacological responsive mouse with DCR-A1203.  
x DCR-A1203 was not genotoxic in the bacterial reverse mutation or in vitro and in vivo 
micronucleus assays. 
Overall, the nonclinical safety program of DCR-A1203 did not iden tify any major safety issues. 
The human relevance of preliminary nonclinical re productive studies is uncl ear, and participants 
will follow contraception guidance. A detailed desc ription of the chemistry and pharmacology of 
DCR-AUD is provided in the Investigator‚Äôs Brochure .  
2.2. Benefit/Risk Assessment 
The summary of potential risks provided below is based on results of the ongoing FIH study 
(DCR-AUD-101 ) and on in-depth review of literature  relating to the proposed approach and 
insights from the nonclinical pharm acology and toxicology studies. 
The antisense sequence of DCR-AUD is designe d to target and reduce the expression of ALDH2  
mRNA in the liver. Potential off-target complement arities at the level of a single mismatch were 
completely absent from the human transcripts analyzed in in-silico studies. These findings demonstrate that DCR-AUD has a high degree of specificity for the ALDH2  mRNA. The 
sequence is conserved in mouse, monkey, and hu man, and therefore, D CR-AUD is active in all 
nonclinical general toxicology species evaluated. To date, DCR-A1203 has been associated with 
no adverse effects in nonclinical studies.  
Clinical experience with the Dicerna GalXC
‚Ñ¢ siRNA platform in more than [ADDRESS_1105256] been reported (Dicerna 
data on file). In addition, in the on-goi ng DCR-AUD-101 trial, single doses of DCR-AUD 
(range: 80 to 960 mg) administered to [ADDRESS_1105257] been mild in severity. 
As part of the study‚Äôs planned mitigation strategy, all study participants will be monitored for 
signs or symptoms of systemic toxicity, dec line in liver or kidney function, abnor malities in 
hematologic parameters (includi ng platelets and coagulation pa rameters), and abnormalities in 
vital signs, ECGs, complement activation, or other relevant safety parameters. 
2.2.1.  Risks Related to DCR-AUD Mechanism of Action 
DCR-AUD, at the proposed dose, is designed to induce mild symptoms resulting from 
substantial alcohol consumption (e.g., ¬ï 4 drinks/occasion) by [CONTACT_800720]2  
mRNA and ALDH2 activity in the liver, and th ereby a decrease in the conversion of 
Dicerna Protocol DCR-AUD-[ADDRESS_1105258] been documented with 
disulfiram treatment and in i ndividuals who are homozygous for ALDH2 -gene‚Äìinactivating 
mutations compared with ALDH2  mutation heterozygotes, propor tional to the magnitude of 
systemic ALDH2 inactivation. 
Study participants will be clearly informed of th ese potential risks. Symptoms that develop with 
concomitant alcohol consumpti on are expected to be sel f-limited and manageable with 
supportive care and can be avoided by [CONTACT_47984]. 
In the absence of direct measur ement of ALDH2 activity in the liver (e.g., via liver biopsy), EIAs 
are necessary to evaluate and confirm DCR-AU D PD activity. The EIAs in this protocol 
([ADDRESS_1105259] drinks [approximately 56 g for men and 48 g for women] administered over an 
80-minute window) are designed to reflect a plausibl e level of consumption for frequent drinkers 
and patients with AUD. Possible signs and symptoms  of alcohol intolerance will be recorded in 
the clinic under close observati on and controlled conditions.  
  
Dicerna Protocol DCR-AUD-102 Version 2.0, 17-Jan-2023 
 Page 25 2.2.2.  Risk Assessment 
Potential Risk of Clinical 
Significance Summary of Data/ 
Rationale for Risk  Mitigation Strategy  
   
Study Intervention: DCR-AUD 
Injection site reactions  Subcutaneous administration of the study intervention may cause a 
specific local reaction originating 
around the injection site, such as 
erythema, itching, discomfort, and 
pain. Most ISRs are mild and self-limiting. 
Participants will be monitored for the 
development of ISRs ( Section 10.3.3
) 
Potential reproductive effects In a preliminary EFD study in 
rabbits with daily SC dosing, maternal toxicity in dams and 
embryofetal effects were observed 
at all dose levels. The human 
relevance of these preliminary 
nonclinical reproductive studies is unclear. All participants of childbearing 
potential are required to practice highly effective contraception consistently throughout the study and for [ADDRESS_1105260] dose of 
study intervention ( Section 10.4
). 
Severe symptoms associated 
with acetaldehyde accumulation following consumption of alcohol In sufficient amounts, acetaldehyde 
accumulation is associated with 
unpleasant effects, including 
flushing, headache, 
lightheadedness, palpi[INVESTIGATOR_814], 
nausea, and vomiting. More severe reactions to acetaldehyde 
accumulation can include copi[INVESTIGATOR_800690], sweating, chest pain, palpi[INVESTIGATOR_332], dyspnea, hypotension, 
syncope, marked uneasiness, 
weakness, vertigo, blurred vision, and confusion. If significant or severe adverse 
V\PSWRPVRFFXULQ¬ï participants 
treated with DCR-AUD during the 
trial, additional DCR-AUD dosing (if 
scheduled) and subsequent EIAs will 
be discontinued. In the event this occurs, all study participants will be advised to avoid alcohol for the entire study observation period.  
Suicidal ideation or behavior 
(SIB) Patients diagnosed with AUD may 
be at risk for SIB. Because 
DCR-AUD is being developed for the treatment of AUD, HV will be 
screened and monitored for the 
presence or emergence of SIB while on study. There is no evidence to suggest that 
HV exposed to DCR-AUD are at risk 
for SIB, however, all participants will 
be monitored for the emergence of SIB 
via the C-SSRS at regular intervals 
throughout the study ( Section [IP_ADDRESS] ). 
Study Procedures 
EIA: alcohol administration may 
cause intoxication and is expected to cause mild, unpleasant effects in participants receiving DCR-AUD 
 Required to assess and confirm 
DCR-AUD PD activity, including magnitude and duration of effects associated with concomitant alcohol interaction During EIAs, alcohol to be 
administered as one standard drink 
every 20 minutes for 4 drinks (i.e., 
over 80 minutes) in a Phase [ADDRESS_1105261] drinking 
histories suggesting tolerability to the 
amount of ethanol to be administered in the EIAs.  
Dicerna Protocol DCR-AUD-102 Version 2.0, 17-Jan-2023 
 Page 26 Potential Risk of Clinical 
Significance Summary of Data/ 
Rationale for Risk  Mitigation Strategy  
   
Blood sampling, including cannulation. Risks include acute pain, bleeding, vessel injury, and, in rare instances, arterial 
vessel blockage, potentially 
leading to infection. Blood sampling is required to 
assess the safety, PK, and PD of DCR-AUD. The total volume of blood to be 
withdrawn for research purposes has 
been limited to the minimum required for a complete assessment. 
Other  
Prolonged PD activity of 
DCR-AUD may cause alcohol intolerance for up to [ADDRESS_1105262](s) resulting from 
high levels of alcohol intake during DCR-AUD treatment is an intentional design element of the DCR-AUD target product profile 
and predicted based on the core 
RNAi/GalXC drug platform.  
The clinical significance is 
expected to be limited to high or very high alcohol consumption, but adverse effects may occur at lower ingested amounts. Ensure risks related to DCR-AUD 
potential PD effects and duration are 
clearly communicated in the informed 
consent. 
Adverse effects related to alcohol 
consumption are self-limited, 
reversible, and avoidable.  
2.2.3.  Benefit Assessment 
There is no expected benefit for HV participants  in the study. Data generated in this study will 
contribute to the development of a potential new therapy for AUD, an area of significant unmet 
medical need, and FDA-a pproved treatment options. 
The siRNA-mediated reduction of ALDH2  via DCR-AUD is designed to offer significant safety 
advantages relative to agents such as di sulfiram, which inhib its multiple aldehyde 
dehydrogenases as well as other enzymes ( Koppaka et al., 2012 ). siRNA-mediated reduction will 
only target ALDH2 in the liver, leaving other aldehyde dehydr ogenases able to function. Further, 
DCR-AUD reduction of ALDH2 w ill be liver-specific, leaving non-liver ALDH2 unaffected.  
2.2.4.  Overall Benefit:Risk Conclusion 
With the measures planned to minimize particip ant risk in this study, the potential risks 
identified in association with DCR-AUD are justif ied by [CONTACT_800721]. 
Dicerna Protocol DCR-AUD-102 Version 2.0, 17-Jan-2023 
 Page 28 4. STUDY DESIGN 
4.1. Overall Design 
This is a double-blind, randomized, placebo-c ontrolled study of DCR-AUD to evaluate the 
safety, tolerability, PK, a nd PD of repeat doses of DCR-AUD in adult HVs.  
Each participant will be screened for up to 28 days. Participants may undergo rescreening one 
time at the discretion of the Investigator or  Sponsor. Screening assessments will include a 
psychological history and a histor y of alcohol consumption using the TLFB method to identify 
participants who are HVs and who meet the min imum inclusion/exclusion alcohol consumption 
requirements. TLFB is a validated method to re trospectively assess dri nking behavior history. 
Randomization and administration of the first dose of study intervention will occur on Day 1. 
Repeated doses of 480 mg study intervention will be administered to 16 adult HVs (12 active and 
4 placebo). Each participant will receive 3 SC  doses of study intervention (on Day 1, Day 29, 
and Day 57). Up to [ADDRESS_1105263] inking history for the study duration. 
Quantitative drinking history will be captured by [CONTACT_800722] 2 weeks. 
Participants will be trained on the use of the diary prior to discharge from the clinic and will 
report on the diary at each visit. 
At the discretion of the Investigator, participants who present with increasing positive ethanol 
reaction symptoms at the Day 168 EIA (e.g., flus hing, headache, lightheadedness, palpi[INVESTIGATOR_814], 
nausea, or vomiting) will be followed fo r an additional 4 weeks (through Day 197). 
4.2. Scientific Rationale for Study Design 
DCR-AUD is designed to selectively reduce ALDH2  mRNA and ALDH2 activity in the liver, 
and thereby [CONTACT_800723]. In 
cynomolgus monkeys, a single SC dose of 3 mg/kg DCR-AUD resulte d in reduction of 
ALDH2 mRNA expression in liver up to 112 days pos tdose, with maximum reduction observed 
at 4 weeks postdose.  
Study DCR-AUD-101  was designed to evaluate the safety, tolerability, PK, and PD of single 
ascending doses of DCR-AUD in healthy adult vol unteers who abstained from drinking alcohol 
during the study (outside of th e study-mandated EIAs). In that  first-in-human (FIH) study, 
DCR-AUD, at doses ranging from [ADDRESS_1105264] (resulting from cumulative ALDH2  mRNA knock down) can be observed in a population 
of social drinkers. Knockdown of ALDH2 activ ity by [CONTACT_47987]-AUD that is sufficient to increase 
plasma acetaldehyde levels and induce symptoms  may require both repeat doses and several 
months to be manifest, supporting the 24-week follow-up observation period in this trial.  
Dicerna Protocol DCR-AUD-[ADDRESS_1105265] 
the drinking patterns experienced by [CONTACT_800724].  
4.3. Justification for Dose 
The dose level of 480 mg was selected followi ng evaluation of nonclini cal PK/PD and safety 
data and based on results of the on-going DCR-AUD-101 study evaluating single ascending 
doses up to 960 mg. 
Administration of DCR-A1203 in the repeat-dose studies for up to 6 months in mice and 9 
months in monkeys resulted in no adverse fi ndings related to DCR-A1203. The NOAEL in the 
mouse and monkey chronic repeat -dose toxicity studies was considered to be 300 mg/kg, the 
highest dose level administered.  
Interim results from DCR-AUD-[ADDRESS_1105266] completed the study if he /she has completed all of the 
Day 169 EOS assessments, as shown in the SoA ( Section 1.3 ). The conditional follow-up visit is 
not required of all partic ipants and is conducted only at the discretion of the Investigator, based 
on the occurrence of substantial symptoms duri ng the Day [ADDRESS_1105267] participant in the study. 
Dicerna Protocol DCR-AUD-102 Version 2.0, 17-Jan-2023 
 Page 30 5. STUDY POPULATION 
Sixteen participants are planned to be enro lled in this study: 12 will receive DCR-AUD and 
4 will receive placebo. 
Protocol waivers or exemptions are not allowe d. Participants may underg o rescreening one time 
at the discretion of the In vestigator or Sponsor ( Section 5.4 )  
5.1. Inclusion Criteria 
Participants are eligible to be included in the study only if all the following criteria apply.  
Age 
1. 21 to 65 years, inclusive, at the time of signing informed consent. 
Type of Participant and Disease Characteristics 
2. Overtly healthy volunteers, as determined  by [CONTACT_629331], physical examinati on, and laboratory testing. 
3. No diagnosis of AUD within the preceding 12 months per Diagnostic and Statistical 
Manual of Mental Disorders (DSM-5). 
4. Social drinkers who consume, on average, [ADDRESS_1105268] by [CONTACT_800716] 
(i.e., AST, ALT, GGT, total bilirubin < 1.[ADDRESS_1105269] at Screening and 'D\√≠ ).  
6. eGFR ¬ï 60 mL/min/1.73 m2 at Screening. 
7. No history of significant adverse reaction(s) to  alcohol. Participant should be expected to 
tolerate the amount of alc ohol administered during EIAs. 
8. Willing to participate in up to [ADDRESS_1105270] for SARS-CoV- LQIHFWLRQRQ'D\√≠ . 
10. Systolic BP in the range of 80 to 140 mmHg and diastolic BP in the range of 50 to 
95 mmHg at Screening. If out of range, BP may be repeated once at the discretion of the 
Investigator. 
Sex and Contraceptive Requirements 
11. Male or female  
‚Ä¢ Male participants with pa rtners of childbearing potential must agree to use 
contraception from Screening through at l east [ADDRESS_1105271] dose of study 
intervention and refrain from dona ting sperm during this period (see Section 10.4 ).  
‚Ä¢ Female participants may not be pregnant or breastfeedi ng, and at least one of the 
following conditions must apply:  
√≠ Is not a woman of childbearing potential (WOCBP) or  
Dicerna Protocol DCR-AUD-[ADDRESS_1105272] agree to follow the contraceptive guidance (see Section 10.4 ), 
beginning at consent and the first Screeni ng visit and for at least [ADDRESS_1105273] dose of study intervention. 
Weight   
12. BMI within the range 18.0 to 32.0 kg/m2 (inclusive).  
Informed Consent  
13. Capable of giving signed informed consen t, which includes compliance with the 
requirements and restrict ions listed in the ICF and in this protocol. 
5.2. Exclusion Criteria 
Participants are excluded from the study if any of the following criteria apply. 
Medical Conditions 
1. History of any medical condition that ma y interfere with th e metabolism of study 
intervention or with the clinical and laboratory assessments in this study.  
2. History of serious, persistent medical c onditions, including liver, gastrointestinal, 
pulmonary, renal, or cardiovascular abnormalities.  
3. History of suicidal attempt at any time or an answer of ‚Äúyes‚Äù on any of the following 
items in the C-SSRS at Screening:  
a. Items 1 or 2 of the Suicidal Ideation sec tion, if ideation occurred in the previous 
12 months.  
b. Items 4 or 5 of the Suicidal Ideation section, in lifetime.  
c. Any item of the Suicidal Behavior section of the C-SSRS, in lifetime. 
4. Any history of severe or recen t clinically significant depre ssion, anxiety, bipolar disorder, 
schizophrenia, or other neuropsychiatric di sorder that, in the judgement of the 
Investigator, represents a safety risk to the participant were they to participate in the trial, 
as informed by [CONTACT_2299]‚Äôs medical hist ory and/or responses to the MINI Screen 
Questionnaire. 
5. History of substance use disorder (SUD) or illicit drug use (excluding cannabis) within 
the preceding 12 months. 
6. History of alcohol withdrawal symptoms including delirium tremen s or alcohol-related 
seizures. 
7. Any condition that, in the opi[INVESTIGATOR_2511] I nvestigator, would ma ke the participant 
unsuitable for participation or could interfere with participation in or completion of the 
study, including: 
a. Poorly controlled or unstable hypertension. 
b. Diabetes mellitus treated with insulin or  hypoglycemic agents (including metformin) 
or HbA 1C > 7%. 
Dicerna Protocol DCR-AUD-102 Version 2.0, 17-Jan-2023 
 Page 32 c. Asthma requiring hospi[INVESTIGATOR_800691] 12 months. NOTE: Persons 
with clinically stable asthma who have not been hospi[INVESTIGATOR_800692] d medications are not excluded. 
d. Currently poorly controlled endocrine conditions, except for hypothyroidism that is 
stable (no treatment change in prior 6 months). 
e. Significant infection or known systemic in flammatory process ongoing at Screening. 
f. History of chronic or recurrent UTI, or  UTI within [ADDRESS_1105274] by [CONTACT_2299]‚Äôs physician or health care provider.  
10. SARS-CoV-[ADDRESS_1105275] administration of study 
intervention. 
Prior/Concomitant Therapy  
12. History of multiple drug allergies or a history of allerg ic reaction to an oligonucleotide-
based therapy.  
13. Use of prescription medications (excep t for hormonal replacement/contraceptive 
medication for women and inhaled medication for treatment of clinically stable asthma) 
within 14 days or 5 half-lives (whichever is longer) prior to administration of study 
intervention. Participants being treated fo r hypothyroid disease must be on stable 
treatment (no treatment  changes in the preceding 6 months).  
14. Receipt of any vaccine (including COVID-19) within [ADDRESS_1105276] 
administration of study intervention.  
15. Regular use of OTC medications, including NSAID (periodic or occasional NSAID use 
to control temporary pain is not exclusionary).  
Prior/Concurrent Clinical Study Experience  
16. Previously participated in  Dicerna Study DCR-AUD-101. 
17. Has received an investigational agent within 30 days or 5 half-lives (whichever is longer) 
prior to dosing or is in follow-up of another clinical study prior to initial dosing with the 
study intervention. 
Diagnostic Assessments  
18. Clinically significant abnormalitie s in vital signs at Screeni ng: pulse rate (< 40 bpm or 
> 90 bpm), respi[INVESTIGATOR_697], or temperature. 
19. Clinically significant abnorma lities in 12-lead ECG at Screening or predose on Day 1, 
including QTcF > 470 msec in females and > [ADDRESS_1105277] at Screening RU'D\√≠ 1. Tests positive for cannabis are not 
exclusionary. 
Dicerna Protocol DCR-AUD-102 Version 2.0, 17-Jan-2023 
 Page 33 21. Seropositive for antibodies to HIV, HBV, or HC V at Screening (historical testing may be 
used if performed within the 3 months prior to screening). NOTE: In participants with 
previous treatment for hepatitis C with di rect-acting HCV medica tion and seropositivity 
for HCV, or in participants with prior infection and spontaneous resolution, HCV RNA 
must be undetectable (at least [ADDRESS_1105278] 12 weeks apart), and 
the HCV infection must have been resolved or cured > [ADDRESS_1105279] result  at Screening considered c linically unacceptable for study 
participation by [CONTACT_737]. 
Other Exclusions  
23. History of intolerance to SC  injection(s) or significant abdominal scarring that could 
potentially hinder study intervention administrati on or evaluation of local injection site 
tolerability.  
24. Scheduled for an elective surgical proc edure during the conduct of this study.  
25. Donation of > [ADDRESS_1105280] on the day of the study visit.  
2. Study participants will be advised to avoid consuming more than 4 drinks during any 
drinking session outside of in-clinic EIAs.  
3. Study participants will be instructed to stop drinking at the onset of any ethanol reaction 
symptoms during outside drinking sessions. 
4. Tobacco/nicotine use is not restricted. 
5. Study participants are to refrain from using cannabis for [ADDRESS_1105281]  on the day of the study visit.  
Activity 
1. Study participants should abstain from strenuous  exercise for 24 hours before each blood 
collection for clinical laboratory tests. Participants may participate in light recreational 
activities (e.g., walking at a pace < 3 miles pe r hour, shoppi[INVESTIGATOR_007], watering plants) in that 
24-hour time period. 
Meals and Dietary Restrictions 
1. For each EIA study visit, participants will be re quired to fast for at least 3 hours and then 
will be fed a standardized meal in the clinic prior to administration of ETOH for the EIA.  
Dicerna Protocol DCR-AUD-102 Version 2.0, 17-Jan-2023 
 Page 34 5.4. Screen Failures 
Screen failures are defined as participants who co nsent to participate in the clinical study but are 
not subsequently randomly assigned to study in tervention. A minimal set of screen failure 
information is required to ensure transparent reporting of screen failure participants to meet the Consolidated Standards of Reporting Trials (CONSORT) pub lishing requirements and to 
respond to queries from regulatory authorities.  Minimal informati on includes demography, 
screen failure details, eligibility criteria, and any SAEs.  
Individuals who do not meet the criteria for part icipation in this study (screen failure) may be 
rescreened. Participants may undergo rescreening one time at the discretion of the Investigator or 
Sponsor. Among blood tests, only pregnancy, hema tology, chemistry, and co agulation tests may 
be repeated. Blood pressure, hear t rate, and ECG may be repeated  for participants who have 
abnormal readings but who are otherwise healt hy, and, in the opi[INVESTIGATOR_689], the 
abnormal values reflect a tran sient departure from the range permitted for eligibility.  
Dicerna Protocol DCR-AUD-102 Version 2.0, 17-Jan-2023 
 Page 35 6. STUDY INTERVENTION 
Study intervention is defined as any investiga tional intervention(s), including placebo, intended 
to be administered to a study participant according to the study protocol. 
6.1. Study Intervention(s) Administered 
The clinical dose is expressed in terms of the weight of the DCR-AUD free acid, rather than that 
of the sodium salt ( Table 4 ). 
Table 4: Study Intervention Administered  
Arm Name [CONTACT_800744]-AUD Physiologic saline (0.9% aqueous 
sodium chloride) for injection 
Intervention Type Drug Drug 
Dose Formulation solution for injection n/a 
Unit Dose Strength 160 mg/mL  n/a 
Dose Level(s) and Frequency 480 mg Q4W √ó 3 Volume to match active, Q4W √ó 3 
Route of Administration SC injection (thigh or abdomen) SC injection (thigh or abdomen) 
Use Experimental Placebo comparator 
IMP or NIMP IMP n/a 
Sourcing Provided centrally by [CONTACT_800725] 
(Pharmacy staff is not blinded) 
Packaging and Labeling DCR-AUD will be provided in vials. 
Each vial will be labeled as required per country. n/a 
Abbreviations: IMP: investigational medicinal product; n/a: not applicable; NIMP: non-investigational medicinal product; 
Q4W: once every 4 weeks; SC: subcutaneous 
 
6.2. Preparation/Handling/Storage/Accountability 
6.2.1.  Handling and Accountability 
The Investigator or designee must confirm ap propriate temperature conditions have been 
maintained during transit for all study interven tion received and that any discrepancies are 
reported and resolved before use of the study intervention. 
Only participants enrolled in the study may recei ve study intervention, and only authorized site 
staff may supply or administer study intervention.  
The Investigator, institution, or the head of the medical institution (where applicable) is 
responsible for study intervention accountabilit y, reconciliation, and r ecord maintenance 
(i.e., receipt, reconciliation, a nd final disposition records). 
Further guidance and information for the fina l disposition of unused study intervention are 
provided in the Pharmacy Manual. 
Dicerna Protocol DCR-AUD-102 Version 2.0, 17-Jan-2023 
 Page 36 6.2.2.  Storage 
DCR-AUD is to be stored at or below 30¬∞C (inclusive). Do not freeze.  
All study intervention must be stored in a s ecure, environmentally c ontrolled and monitored 
(manual or automated) area in accordance with the labeled storage conditions, with access limited to the Investigator and authorized site staff. 
The placebo comparator should be stored in accordance with the product labeling. 
6.2.3.  Preparation and Administration 
Study intervention will be prepared by [CONTACT_8868]. A second 
medically qualified person must check the dose preparation prior to administration to be sure the correct dose has been prepared.  
If stored at 2¬∞C to 8¬∞C, DCR-AUD should be allowed to warm to room temperature for 
approximately 1 hour be fore administration.  
DCR-AUD is administered as a SC injection in to the thigh or abdomen. The maximum volume 
of a single SC injection should not exceed 1.5 mL ; the total dose will be administered as 2 SC 
injections of equal volume at se parate injection sites, prefer ably in separate quadrants.  
Placebo will be administered as an SC injection of physiologi c saline (0.9% aqueous sodium 
chloride) in the thigh or abdomen at a volume equal to that of DCR-AUD.  
All used DCR-AUD vials will be retained and quarantined in the pharmacy. Once drug 
accountability is recorded to be accurate, the vial s will be destroyed on s ite per clinic SOP. 
Complete details will be provided in the Pharmacy Manual. 
6.3. Measures to Minimize Bias: Randomization and Blinding 
This is a randomized, placebo-controlled, double-b lind study, where the Investigators, study site 
personnel (excluding pharmacy staff), CRO staff, and study participants will be blinded for the 
duration of the study. Some member s of the Sponsor team will be unblinded for the duration of 
the study. This enables the Sponsor to immediately and comprehensively evaluate the safety of 
the study participants. Complete  details will be presented in the Study Blinding Plan.  
The overall DCR-AUD to placebo ratio is 3:1. All participants will be centrally assigned to 
randomized study intervention using an Interac tive Voice/Web Response System (IVRS/IWRS). 
Before the study is initiated, the telephone number and call-in direc tions for the IVRS and/or the 
log in information and directions  for the IWRS will be provided to each site. To maintain the 
study blind, the unblinded site pharmacy staff w ill be responsible for the preparation and 
dispensing of all study intervention. 
In the event of a Quality Assurance audit, th e auditor(s) will be allowed access to unblinded 
study intervention records at the site(s) to veri fy that randomization/dispensing has been done 
accurately.  
The IVRS/IWRS will be programmed with blind-breaking instructions. In case of an emergency, 
the Investigator has the sole responsibility fo r determining if unblindi ng of a participant‚Äôs 
treatment assignment is warranted. Participant safety must always be the first consideration in 
making such a determination. If the Investigat or decides that unblinding is warranted, the 
Dicerna Protocol DCR-AUD-[ADDRESS_1105282] the Medical Monitor prior to unblinding a 
participant‚Äôs treatment assignment, unless th is could delay emergency treatment of the 
participant. If a participant‚Äôs treatment assignment is unblinded, the Medical Monitor must be notified within [ADDRESS_1105283] abstain from taking pres cription or nonprescription drugs within 14 days 
or 5 half-lives (whichever is longer) prior to the first administration of study intervention until 
EOS, with the following exceptions: 
x Regular use of vitamins is acceptable. 
x Hormonal replacement/contraceptive medication for women is acceptable. 
x Inhaled medication for treatment of clinically stable asthma is acceptable.  
x Participants being treated for hypothyroid di sease must be on stable treatment (no 
treatment changes in the preceding 6 months).  
x Occasional use of NSAIDs for pain management is acceptable. Regular use of OTC 
medications (including NSAIDs) is not allowed. 
x Participants must not receive any vaccine from Day √≠14 through Day 71 of the study.  
Any medication or vaccine (incl uding OTC or prescription medici nes, recreational drugs [with 
the exception of cannabis], vitamins, and herbal supplements) that the participant is receiving at the time of enrollment or receives during th e study must be recorded along with:  
1. Reason for use.  
2. Dates of administration, incl uding start and end dates. 
3. Dosage information, including dose and frequency. 
Dicerna Protocol DCR-AUD-102 Version 2.0, 17-Jan-2023 
 Page 38 6.7.1.  Rescue Medicine 
Not applicable. 
7. DISCONTINUATION OF STUDY INTERVENTION AND 
PARTICIPANT DISCONTINUATION/WITHDRAWAL 
7.1. Participant Discontinuation/Withdrawal from the Study 
A participant may withdraw from the study at any time at his/her ow n request or may be 
withdrawn at any time at the discretion of the Investigator for safety, behavioral, compliance, or 
administrative reasons.  
If a participant has a significant adverse reac tion to alcohol at the Day ‚Äì1 visit (before 
administration of DCR-AUD), the participant will be discontinued from the study. The 
participant will be replaced.  
If possible, at the time of discontinuing from the study, an early termination (ET) visit should be 
conducted, as shown in the SoA ( Table 1 ).  
If the participant withdraws consent for disclosure  of future information, the Sponsor may retain 
and continue to use any data collected be fore such a withdrawal of consent.  
If a participant withdraws from the study, he/she may request destruction of any samples taken 
and not tested, and the Inves tigator must document this in the site study records.  
The reason for participant discontinuation or wit hdrawal from the study will be recorded on the 
eCRF. Participants who sign the ICF and ar e randomized but do not receive the study 
intervention may be replaced. Par ticipants who sign the ICF, are randomized and do receive the 
study intervention and subsequen tly withdraw or are withdraw n or discontinued from the study 
may be replaced at the discretion of the Sponsor. 
7.2. Lost to Follow Up 
A participant will be considered lost to follow-up if he or she repeatedly fails to return for 
scheduled visits and is unable to be contact[CONTACT_800726][INVESTIGATOR_800693].  
The following actions must be taken if a participant fails to return to the clinic for a required 
study visit:  
x The site must attempt to contact [CONTACT_364953]/or 
should continue in the study.  
x Before a participant is deemed lost to follow up, the Investigator or designee must 
make every effort to regain contact [CONTACT_6635] (where  possible, 3 telephone 
calls and, if necessary, a certified letter to the part icipant‚Äôs last known mailing 
address or local equivalent  methods). These contact a ttempts should be documented 
in the participant‚Äôs medical record.  
Dicerna Protocol DCR-AUD-102 Version 2.0, 17-Jan-2023 
 Page 39 x Should the participant continue to be unreach able, he/she will be considered to have 
withdrawn from the study. 
7.3. Individual Participant Stoppi[INVESTIGATOR_1869] 
7.3.1.  Serious Adverse Event 
If a participant experiences an SAE ( Section 10.3.2 ), unless it is clearly the result of a non-study-
related event, further dosing of the participant will be paused while the SRC reviews the event. 
Based on this review, a decision will be made as to whether the participant may continue to receive doses of study intervention. In partic ipants who have completed dosing, continued 
follow-up with protocol-specified assessments, including subsequent EIAs, will be pursued if the 
participant is willing and the PI [INVESTIGATOR_800694].
 Additional EIAs will not be 
performed if, in the clinical judgment of the PI  [INVESTIGATOR_1238]/or SRC, the SAE c ould be related to study 
intervention and that repeat EIAs pose a recurrent risk to the participant, or if the participant 
declines these additional assessme nts. Participants will continue  to be followed for other study 
procedures as detailed in the SoA. 
7.3.2.  Abnormal Liver Function Tests 
Discontinuation of study interventi on is required when a participan t meets one of the conditions 
outlined in Section 10.[ADDRESS_1105284] of the participant. 
7.3.3.  Electrocardiogram Findings 
If a clinically significant finding is identified (including, but not limited to, the QTcF findings 
below) after enrollment, the Investigator or qualified designee will determine if the participant 
can continue in the study and if any change in particip ant management is need ed. This review of 
the ECG printed at the time of collection must be documented. Any new clinically relevant finding should be reported as an AE.  
x Absolute QTcF > 500 msec and/or  
x QTcF change of > 60 msec from baseline and >450 msec.  
x New and clinically significant a rrhythmia or r hythm abnormality. 
7.3.4.  Significant Negative Reacti on to Alcohol Ingestion 
Any participant who experiences a significant negati ve reaction to alcohol ingestion that includes 
severe or serial vomiting or he modynamic instability (syncope or si gnificant pre-syncope, or BP 
decline of more than 25 mmHg from Baseline with some lightheaded symptoms, or HR increases to ¬ï 110 bpm with some symptoms during an EIA)  will be discontinued from additional dosing 
and will be advised to no t drink outside of the clinic for th e duration of the study. The participant 
will continue to be followed in the study for ot her protocol-specified procedures. The PI [INVESTIGATOR_800695]/s ubsequent protocol-specified EIAs  will be conducted, based on the 
nature and severity of symptoms observed. 
See Section [IP_ADDRESS]  regarding full details on stoppi[INVESTIGATOR_800696]. 
Dicerna Protocol DCR-AUD-102 Version 2.0, 17-Jan-2023 
 Page 40 7.4. Study Stoppi[INVESTIGATOR_800697]:  
x 2 participants develop a Grade 3 CTCAE even t, unless it is clearly the result of a non-
study-related event.  
x SDUWLFLSDQWGHYHORSVD ¬ï*UDGH&7&$(HYHQW , unless it is clearly the result of a 
non-study-related event. 
All further DCR-AUD dosing and subsequent EIAs  will be stopped if the following occurs AND 
the SRC recommends stoppi[INVESTIGATOR_10098]: 
x [ADDRESS_1105285] that an external, inde pendent, unblinded DSMC be convened to review the decision and 
make a recommendation to the SRC as to whet her the study should stop or continue with no 
changes or continue with a ppropriate modifications to a ddress the safety concern (see 
Section 10.1.5 ). Should the DSMC recommend stoppi[INVESTIGATOR_10098], all ongoing participants will 
continue to be followed for safety assessments as indicated in the schedule of activities.  
The Sponsor will promptly notify the s ite if study stoppi[INVESTIGATOR_47940]. 
8. STUDY ASSESSMENTS AND PROCEDURES 
Study procedures and their timing are summarized in Section 1.3 . Adherence to the study design 
requirements, including those specified in Table 1, Table 2 , and Table 3  (Section 1.3 ) is essential 
and required for study conduct.  
Protocol waivers or exemptions are not allowe d. Participants may underg o rescreening one time 
at the discretion of the In vestigator or Sponsor ( Section 5.4 ). 
Urgent safety concerns should be discussed with the Sponsor  immediately upon occurrence or 
awareness.  
Participants will be given a di ary to track AEs associated with alcohol intake for the study 
duration. Participants will be trained on the use of the diary prior to discharge from the clinic for 
Week 1 and will report on the diary at each visit.  
If multiple assessments are due, the order of prio rity should be ECG, vitals, blood draws, and 
then other assessments.  
The maximum amount of blood drawn from each pa rticipant (including PK, biomarker, and 
safety laboratory testi ng) will not exceed 550 mL over an 8-week period. 
8.1. Efficacy Assessments 
This is a Phase 1 study with the primary objectiv e of evaluating safety. Pharmacokinetic and PD 
assessments are detailed in Section 8.5  and Section 8.6 , respectively.  
Dicerna Protocol DCR-AUD-102 Version 2.0, 17-Jan-2023 
 Page 41 As the study participants are HV not diagnosed with AUD, no true assessment of efficacy can be 
made. However, study participants may be inclined to change th eir alcohol intake should they 
experience physiologic symptoms associated with increased ac etaldehyde while drinking. As 
such, 2 assessments of alcohol  intake, TLFB and PEth, will be  considered in exploratory 
analyses. 
8.1.1.  Alcohol Consumption via Timeline Follow Back 
Participants will complete the TLFB at screen ing and throughout the study period to capture any 
change in drinking behavior. At every visit, the TLFB will be used to assess each participant‚Äôs 
alcohol consumption for the 2-week pe riod that precedes the study visit.  
The TLFB was developed as a procedur e to aid recall of past drinking ( Sobell & Sobell, 1992 ). 
Currently, self-reports are the only viable met hod for retrospectively measuring drinking with 
any precision. Alternative methods exist, but they are either impractical (e.g., continuous direct 
observation), fraught with problem s (e.g., alcohol sweat patches), or they only measure very 
recent drinking (e.g., blood alcohol  tests). TLFB stands as the most exhaustively evaluated 
method that can be used to retrospec tively assess drinking behavior over time. 
8.1.2.  Blood Phosphatidylethanol Levels 
Hepatic ethanol oxidation is the prevalent route of human ethanol metabolism, eliminating more 
than 90% of ingested ethanol. Several nonoxidative rout es of ethanol metabolism that result in 
the enzymatic conjugation of et hanol to endogenous me tabolites have also been described. Due 
to slower elimination rates, these nonoxidative ethanol metabolite s persist in body fluids and 
tissues for much longer than etha nol itself, thus enabling the retr ospective assessment of ethanol 
intake even when ethanol itself is no longer present in the body. 
Phosphatidylethanol (PEth) is a phospholipid produ ced in erythrocyte membranes after alcohol 
exposure, first described by [CONTACT_800727]. ( 1983 ). In drinking experiment s, PEth production began 
as soon as ethanol was consumed and peak ed 1 to 3 hours after alcohol consumption 
(Gnann et al., 2012 ; Heier et al., 2016 ). With frequent alcohol c onsumption, and a half-life of 
approximately 5 days, PEth accumulates in whole blood ( Javors et al., 2016 ). Because PEth can 
be detected in blood for up to one month after one-time alcohol intake, it can be used as a 
biomarker to determine both cu rrent and recent consumption ( Kummer et al., 2016 ).  
Ulwelling & Smith ( 2018 ) proposed 3 ranges of PEth values  likely to describe a person‚Äôs 
average recent alcohol consum ption/drinking behavior:  
x <20 ng/mL  Abstinence or light drinking (0 to <2 drinks/day) 
x 20 ‚Äì 199 ng/mL Moderate drinking (2 to 4 drinks/day for several days a week) 
x > 200 ng/mL Heavy drinking (at least 4 drinks/day for several days a week) 
Thus, PEth may be used to identify and/or mon itor individuals with chronic excessive drinking 
behavior ( Viel et al., 2012 ). 
8.2. Safety Assessments 
Planned time points for all safety assessments are provided in the SoA ( Section 1.3 ). Safety 
assessments will be conduc ted in all participants at every study visit unless ot herwise specified. 
Dicerna Protocol DCR-AUD-[ADDRESS_1105286] udy-specific instruments (see the Study 
Reference Manual). 
8.2.1.  Screening Tests 
All screening evaluations must be completed and reviewed to confirm that potential participants 
meet all eligibility criteria. The Investigator will maintain a screening log to record details of all 
participants screened and to confirm eligibility or record reasons for screening failure, as 
applicable. 
[IP_ADDRESS].  Mini-International Neuropsychiatric Interview 
The MINI Screen is a brief structured diagnostic  interview to meet the need for a short but 
accurate structured psychi atric interview for multicen ter clinical trials ( Sheehan et al., 1998 ). 
This validated tool can be administered in a short period of time (approximately 15 minutes) and 
will be administered at screening to exclude participants with major psychiatric disorders. The MINI Screen will be administered by a Health Care Provider. 
[IP_ADDRESS].  Laboratory Tests to Determine Eligibility 
In addition to the hematology, clin ical chemistry, coagulation, and ur inalysis panels indicated in 
Table 6,  the following tests will be performed during screening: 
x Follicle-stimulating hormone  (as needed to confirm menopausal status) 
x Viral serology (human immunodeficiency virus antibody, hepatitis B surface antigen, 
and hepatitis C virus antibody) 
x Hemoglobin A
1c 
x Urine drug screen (to include, at a minimu m, amphetamines, barbiturates, cocaine, 
opi[INVESTIGATOR_858], and benzodiazepi[INVESTIGATOR_1651]) 
8.2.2.  Physical Examinations 
Complete physical examinations will be conducted at every visit.  Physical examinations will 
include, at a minimum, assessments of the Cardiovascular, Respi[INVESTIGATOR_696], Gastrointestinal, Neurological, and Skin systems. He ight will be measured and reco rded at Screening. Weight will 
be measured and recorded at every visit.  
x Investigators should pay special attention to clinical signs related to previous serious 
illnesses or AEs. 
x All physical examinations should include  inspection of the injection site. 
8.2.3.  Vital Signs 
Temperature by [CONTACT_47996], pul se rate, respi[INVESTIGATOR_697], and blood pressure  will be assessed, 
unless otherwise indicated in the SoA.  
Blood pressure and pulse measuremen ts will be assessed in the seated position with a completely 
automated device. Manual techniques will be used only if an automated device is not available. 
Dicerna Protocol DCR-AUD-[ADDRESS_1105287] for the 
participant in a quiet setting without di stractions (e.g., tele vision, cell phones).  
Temperature will be obtained in degrees Celsius (¬∞C), pulse rate will be counted for a full minute 
and recorded in beats per minute, and respi[INVESTIGATOR_800698] a full minute and recorded 
in breaths per minute.  
Note: In addition to standard vital sign measurements for safety, vital signs will be recorded as 
part of the EIA and results will be identifie d as such (e.g., HR for EIA) in the eCRF 
8.2.4.  Electrocardiograms 
Standard 12-lead ECGs will be performed in the supi[INVESTIGATOR_47944] 5 minutes. ECGs will be obtained using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and corrected QT interval (QTcF, Fridericia 
correction). Refer to Section 7.3.3  for QTc withdrawal criteria a nd any additional readings that 
may be necessary. Screening ECGs may not be repeated for determination of eligibility. 
The Investigator or designee is responsible for re viewing the ECGs to assess whether the results 
are within normal limits and to determine the clinical significance of the results. These 
assessments will be recorded on the CRF.  
ECGs also will be conducted for EIA assessments. Th ese ECG results will be recorded as part of 
the EIA and will be identified as such (e.g., ECG for EIA) in the CRF. 
Note: If multiple assessments are due, the order of  priority should be ECG, vitals, blood draws, 
and then other assessments, with the PK sampli ng being performed preferably at the nominal 
time point.  
8.2.5.  Suicidal Ideation and Behavior Risk Monitoring 
Patients diagnosed with AUD may be at risk for SIB. Because DCR-AUD is  being developed for 
the treatment of AUD, HV will be screened and monitored for the presence or emergence of SIB 
while on study. Consideration should be given to discontinuing study interven tion in participants 
who experience signs of SIB, following a risk assessment.  
[IP_ADDRESS].  Columbia-Suicide Severity Rating Scale 
The C-SSRS is a suicidal ideation rating scale created by [CONTACT_457318] 
(Posner et al., 2011 ). It rates an individual's degree of suicidal ideation on a scale, ranging from 
‚Äúwish to be dead‚Äù to ‚Äúactive suicidal ideation with specific plan and intent.‚Äù  
The scale identifies behaviors that may be indicative of an individual's intent to commit suicide. 
The C-SSRS is used extensively across primary care, clinical practice, surveillance, research, and 
institutional settings and is part  of a national and internationa l public health initiative involving 
the assessment of suicidal idea tion and behavior. The C-SSRS requires no mental health or 
medical training to administer it. The C-SSRS wi ll be administered by [CONTACT_800728]. 
The Baseline version will be administered at Screening and at subsequent visits the ‚ÄúC-SSRS 
Since Last Visit‚Äù version will be administered. 
Dicerna Protocol DCR-AUD-[ADDRESS_1105288] of clinical laboratory tests to be performed and the SoAs 
(Section 1.3 ) for the timing and frequency.  
The Investigator must review the laboratory re port, document this review in the eCRF, and 
record any clinically relevant changes occurring during the study in  the AE section of the eCRF. 
The laboratory reports must be filed with the source documents. 
All laboratory tests with values considered clinically signifi cantly abnormal dur ing participation 
in the study should be repeated (central laborator y) until the values return to normal or stabilize 
at a level no longer considered c linically significant by [CONTACT_47998].  
x If such values do not return to normal/baseline within a period of time judged 
reasonable by [CONTACT_737], the etiol ogy should be identified, and the Sponsor 
notified.  
x All protocol-required laboratory  assessments, as defined in Section 10.[ADDRESS_1105289] be 
conducted in accordance with the Laboratory Manual and the SoA ( Section 1.3 ).  
x If laboratory values from non-protocol speci fied laboratory assessments performed at 
the institution‚Äôs local laboratory require a change in participant management or are 
considered clinically significant by [CONTACT_18413] (e.g., SAE or AE), then the results 
must be recorded in the eCRF. 
8.2.7.  Pregnancy Testing 
WOCBP should only be included after a confir med menstrual period and a negative highly 
sensitive urine or serum pregnancy test. If a urine test is positive, it must be confirmed with a serum test. See Section 8.3.[ADDRESS_1105290] udy participant or the partner of a 
male participant. 
Additional pregnanc y testing should be performed  as indicated in SoA ( Section 1.3 ). 
Pregnancy testing will be performed whenever a menstrual cycle is missed or when pregnancy is 
otherwise suspected.  
Pregnancy testing with a sensitivity of at least 25 mIU/mL will be performed. 
8.3. Adverse Events, Serious Adverse Events, and Other Safety 
Reporting 
The definitions of AEs, SAEs, and adverse events  of special interest (AESI) can be found in 
Section 10.3.1 , Section 10.3.2 , and Section 10.3.3 , respectively.  
The Investigator and any qualif ied designees are responsible for detecting, documenting, and 
recording events that meet the definition of an  AE or SAE and remain responsible for following 
up AEs that are severe or serious, and consid ered related to the study intervention or study 
procedures, or that caused the participant to discontinue study intervention or the study. 
Dicerna Protocol DCR-AUD-[ADDRESS_1105291] follow-up 
visit at the time points specified in the SoAs ( Section 1.3 ).  
All SAEs will be recorded and re ported to the Sponsor or design ee within 24 hours, as indicated 
in Section 10.3.5 . The Investigator will submit any update d SAE data to the Sponsor within 
24 hours of it being available.  
Investigators are not obligated to actively seek AE or SAE after conclusion of study 
participation. However, if the I nvestigator learns of any SAE, including a death, at any time after 
a participant has been discharged from the study, a nd he/she considers the event to be reasonably 
related to the study intervention or  study participation, the Investigator must promptly notify the 
Sponsor. 
8.3.2.  Method of Detecting AEs and SAEs 
The method of recording, evaluating, and assessi ng causality of AE and SAE and the procedures 
for completing and transmitting SAE reports are provided in Section 10.3 . 
Care will be taken not to introduce bias when detecting AE s and/or SAEs. Open-ended and non-
leading verbal questioning of the participant is the preferred method to inquire about AE 
occurrences. 
Injection sites will be examined by [CONTACT_800729] ( Section 10.3.3 ). 
8.3.3.  Follow-up of AEs and SAEs 
After the initial AE/SAE report, the Investigator is required to proactively follow each 
participant at subsequent visits/contacts. All SAEs and AESIs (as defined in Section 10.3.3 ), will 
be followed until resolution, stabilization, the event is  otherwise explained, or the participant is 
lost to follow-up (as defined in Section 7.2 ). Further information on follow-up procedures is 
provided in Section 10.3.[ADDRESS_1105292] udy intervention under clinical investigation. The 
Sponsor will comply with country-specific regulator y requirements relating to  safety reporting to 
the regulatory authority, IRBs/IECs, and Investigators.  
Investigator safety reports must be prepared for suspected unexpected se rious adverse reactions 
(S[LOCATION_003]R) according to local re gulatory requirements and Spons or policy and forwarded to 
Investigators as necessary. 
An Investigator who receives an Investigator sa fety report describing a SAE or other specific 
safety information (e.g., summary or  listing of SAEs) from the Sponsor  will review and then file 
Dicerna Protocol DCR-AUD-102 Version 2.0, 17-Jan-2023 
 Page 46 it with the Investigator‚Äôs Brochur e and will notify the IRB/IEC, if appropriate, according to local 
requirements. 
8.3.5.  Pregnancy 
Details of all pregnancies in female participants and female partners of male participants will be 
collected after the start of study intervention and until [ADDRESS_1105293] dose.  
If a pregnancy is reported, the Investigator should inform the Sponsor within 24 hours of 
learning of the pregnancy and should follow the procedures outlined in Section 10.4.3 .  
While pregnancy itself is not cons idered to be an AE or SAE,  any pregnancy complication or 
elective termination of a pregnancy for medical reasons will be reported as an AE or SAE. 
Abnormal pregnancy outcomes (e .g., spontaneous abortion, fetal death, stillbirth, congenital 
anomalies, ectopic pregnancy) are considered SAEs.  
The participant or pregnant partner will be followed to determine the outcome of the pregnancy. 
The Investigator will collect follow-up information on the participant or pregnant partner and the neonate, and the information will be forwarded to the Sponsor.  
Any post-study pregnancy -related SAE considered reasonably related to the study intervention 
by [CONTACT_9341] 8.3.[ADDRESS_1105294] udy participants, he or 
she may learn of an SAE through spontaneous reporting. 
8.4. Treatment of Overdose 
For this study, any dose of DCR-AUD greater than  960 mg will be considered an overdose. 
The Sponsor does not recommend specifi c treatment for an overdose.  
In the event of an overdose, the Investigator should:  
x Keep the participant under observation at least overnight. The Investigator will use 
his or her judgment to determine if it is safe for the participant to undergo the EIA 
scheduled for that visit. 
x Closely monitor the participant for a ny AEs or laborato ry abnormalities until 
DCR-AUD PD effects can no longer be detected.  
x Contact [CONTACT_9306].  
x Document the quantity of the excess dose. 
It should be noted that an overdose is  not an AE, in and of itself. See Section 10.3.1  for details. 
8.5. Pharmacokinetics 
Blood samples (2 mL) will be collected for meas urement of plasma concentrations of DCR-AUD 
and its metabolites as specified in the SoAs (see Section 1.3 ).  
Instructions for the collection and handling of biological samples will be provided by [CONTACT_800730]. The actual date 
and time (24-hour clock time) of ea ch sample will be recorded.  
Dicerna Protocol DCR-AUD-102 Version 2.0, 17-Jan-2023 
 Page 47 Each plasma sample will be di vided into 2 aliquots (one fo r PK and one backup). Samples 
collected for analyses of plasma concentrations of DCR- AUD and its metabolites may also be 
used to evaluate safety or efficacy aspects rela ted to concerns arising during or after the study.  
Pharmacokinetic parameters to be determined may include area under the concentration curve 
(AUC), minimum observed concentration (C min), maximum observed concentration (C max), time 
to maximum concentration (T max), terminal elimination half-life (t 1/2), apparent clearance (CL/F), 
and apparent volume of distribution (Vd/F). Additional parameters may be estimated if deemed appropriate.  
Any changes in the timing or addition of time points for any planned study assessments must be 
documented and approved by [CONTACT_800731] a protocol amendment.  The IRB/IEC will be informed 
of any safety issues that require  alteration of the safety monito ring scheme or amendment of the 
ICF.  
Drug concentration information that may be unblinding will not be reported to investigative sites 
or blinded personnel until the study has been unblinded. 
8.6. Pharmacodynamics 
DCR-AUD is designed to selectively reduce ALDH2 activity in the liver and the conversion of 
acetaldehyde to acetic acid after alcohol cons umption. The build-up of acetaldehyde causes 
unpleasant effects after drinking (e.g., flushing, headache, lighthead edness, palpi[INVESTIGATOR_814], nausea, 
or vomiting). As such, the PD activity of DCR-AUD will be assessed during EIAs via these 6 symptoms, blood biomarkers (ethanol, acet aldehyde, and acetate), and heart rate.  
Published literature consis tently demonstrate that administrati on of low/moderate  alcohol intake 
(0.1 to 0.8 g/kg) in human ALDH2  mutation homo- or heteroz ygotes results in clearly 
differentiated increases in blood acetaldehyde an d heart rate compared with ALDH2 normal 
alleotypic controls ( Bae et al., 2012 ; Peng et al., 1999 ; Peng et al., 2007 ; Nishimura et al., 2002 ; 
Enomoto et al., 1991 ).  
8.6.1.  Ethanol Interaction Assessments 
Serial EIAs will be performed to assess the indirect PD effects of ALDH2 reduction 
(acetaldehyde increase). EIAs will be c onducted in accordance with the SoA in Section 1.[ADDRESS_1105295] for PK sample collections. 
Participants will consume a fixed dose of ethanol mixed in a liquid that has no additional 
alcohol, no caffeine, and is low in sugar. Th e ethanol dose will be 0.8 g/kg (to a maximum of 
56 g) for male participants and 0.68 g/kg (to a maximum of 48 g) for female participants. 
Ethanol will be consumed in 4 equal aliquots over an 80-minut e period (20 minutes for each 
Dicerna Protocol DCR-AUD-102 Version 2.0, 17-Jan-2023 
 Page 48 aliquot). During the EIA, participants will rece ive nothing by [CONTACT_1966] (remain NPO) except water 
ad libitum. Assessments will be made over an estimated 4-hour period, as detailed in Table 3 .  
Participants will remain in the Phase 1 unit fo r over-night observation. The Investigator will not 
discharge any participant expe riencing ongoing effects of ethanol  administration and will not do 
so until it is deemed medically safe to do so. 
[IP_ADDRESS].  EIA Blood Biomarkers 
Blood biomarkers to be assessed include meas urement of acetaldehyde, acetate, and ethanol. 
Blood samples (2 mL) will be collected via a venous access device at the times indicated in 
Table 3 . Additional details regarding blood sample collection and pr ocessing will be detailed in 
the Laboratory Manual. 
As plasma biomarker data may be  unblinding, results will not be repor ted to investigative sites or 
blinded personnel until the study has been unblinded. 
[IP_ADDRESS].  EIA Physiologic Signs and Symptoms 
EIA assessments will include the direct questioning of participants as to the presence of ethanol 
reaction symptoms (flushing, headache, lighthead edness, palpi[INVESTIGATOR_814], na usea, and vomiting) at 
the times indicated in Table 3. Note: the presence of these ethanol reaction symptoms will not be 
considered AEs. 
A composite 6-symptom score for each participant during each EIA will be determined as 
follows: 
x At each of the timepoints during the EIA, each symptom will be given a numeric 
score of 0 (not present) to 3 (present and severe), with the exception of vomiting, 
which will be given a score of 3. 
x The composite symptom score for each of the EIA timepoints will be the summed 
value for each of the 6 symptoms at that timepoint (range 0 ‚Äì 18). 
x The Peak score for a given day's EIA will be the participant‚Äôs highest post-alcohol 
ingestion timepoint score minus the participant‚Äôs pre-alcohol score. 
Vital signs (BP and heart rate) and standard 12-lead ECGs will be recorded at the times indicated 
in Table 3 .  
[IP_ADDRESS].  Stoppi[INVESTIGATOR_800699], administration of alcohol to a participant may be stopped for the 
following physiologic responses, though follow- up EIA assessments will be conducted:  
x Any vomiting or severe nausea (as judged by [CONTACT_10670])  
x Systolic blood pressure increase of > 25 mmHg (or to a level > 160 mmHg) or 
decrease of > 15 mmHg to < 70 mmHg or any decline accompanied by [CONTACT_48005] (pre-syncope, syncope, lightheadedness) 
x Diastolic blood pressure decrease to < 50 mmHg or any decline accompanied by 
[CONTACT_48005] (pre-syncope , syncope, lightheadedness)  
Dicerna Protocol DCR-AUD-102 Version 2.0, 17-Jan-2023 
 Page 49 x HR increase of > 20 beats per minute an d to a level > 100 beats per minute  
x Temperature increase of > 1¬∞Celsius  
x Any clinically meaningful change in affect  or clinical status, per Investigator or 
supervising designee‚Äôs clinical judgment 
[IP_ADDRESS].  Follow-up of Participants Who Continue to have Po sitive Ethanol Reaction 
Symptoms at Day 168 (Conditional Follow-up) 
All participants who have etha nol reaction symptoms during the Day 168 EIA will be instructed 
to continue limit drinking to 4 drinks  or less during any drinking session.  
Participants who present clini cally significant positive ethanol re action symptoms at the Day 168 
EIA (flushing, headache, lightheadedness, palpi[INVESTIGATOR_814] , nausea, or vomiting) that the PI [INVESTIGATOR_800700]/or warranting furt her follow-up, will be followed for an additional 4 weeks (through 
Day 197; see Table 1 ). If symptoms related to ethanol inges tion that the Investigator considers 
relevant are present at Day 197, the Sponsor may re quest continued contact [CONTACT_800732].  
8.6.2.  Presence of Physiologic Symptoms Asso ciated with Consumption of Ethanol 
Outside of EIAs 
Participants will be a llowed to continue drinking alcohol in the windows between study visits, 
but will be advised not to drink more than [ADDRESS_1105296] consented to 
ALDH2  genotypi[INVESTIGATOR_007]. Participation is  optional; participants w ho do not wish to undergo 
genotypi[INVESTIGATOR_800688]. 
In the event of DNA extraction failure, a repl acement genetic blood samp le may be requested 
from the participant. Signed informed consent will be required to obtain a replacement sample, unless it was included in the original consent.  
See Section 10.[ADDRESS_1105297] ruction of these samples can be  found in the Laboratory Manual. 
8.8. Immunogenicity Assessments 
Serum samples for the detection and characteri zation of antibodies to DCR-AUD will be stored 
until a validated assay method is available.  
Dicerna Protocol DCR-AUD-102 Version 2.0, 17-Jan-2023 
 Page 50 Serum samples will be collected at times specified in the SoA ( Section 1.3 ). Additionally, serum 
samples should also be collected at the fina l visit from participants  who discontinued study 
intervention or were withdrawn from the study.  
Serum samples will be screened for antibodies binding to DCR-AUD, and the titer of confirmed 
positive samples will be reported. Other analyses may be performed to verify the stability of 
antibodies to DCR-AUD and/or further char acterize the immunogenicity of DCR-AUD.  
Antibodies may be further charact erized and/or evaluated for their ability to neutralize the 
activity of DCR-AUD.  
8.9. Health Economics 
Health Economics parameters ar e not planned for this study. 
9. STATISTICAL CONSIDERATIONS 
9.1. Statistical Hypotheses 
Statistics will be descriptive. No tests of statistical inference are planned. 
9.2. Sample Size Determination 
No formal sample size estimations were perfor med. The sample size of 16 participants (12 active 
and 4 placebo) was considered suff icient to provide an initial asse ssment of the safety profile of 
DCR-AUD in HVs, and adequate for the pur pose of describing PK/PD data in HVs. 
The sample size is based on clinical rather than statistical considerations. 
Dicerna Protocol DCR-AUD-[ADDRESS_1105298] 1 dose of DCR-AUD or placebo. Participants w ill be 
analyzed according to the initial dose received.  
 
9.4. Statistical Analyses 
The statistical analysis plan (SAP) will be finalized prior to database lock. The SAP will include 
a more technical and detailed descri ption of the statistical analyses described in this section. This 
section is a summary of the planned statisti cal analyses of the most important endpoints 
including primary and key secondary endpoints. 
9.4.1.  General Considerations 
In general, summary statistic s (n, mean, SD, median, minimum,  and maximum for continuous 
variables, and number and percenta ge of participants in each cat egory for categorical variables) 
will be provided for all variables.  
Baseline is defined as the last non-missing measurement prior to the date and time of the dose of 
study intervention. 
All analyses will be based on observed data w ithout imputation for missing values. Except for 
outlier analyses, measurements collected from unscheduled visits will not be included in the 
summary tables or figures but will be included in the participant listings. Source data for the 
summary tables and statistical analyses will be presented as participant data listings. 
Dicerna Protocol DCR-AUD-102 Version 2.0, 17-Jan-2023 
 Page 52 9.4.2.  Primary Endpoint(s) 
The primary endpoints of the study are the assessme nt of the incidence and severity of AEs and 
SAEs, and the changes from baseline in vital signs , 12-lead ECG, clinical laboratory tests, and 
physical examination findings. 
All safety analyses will be performed on the Sa fety Population. Adverse events will be defined 
as treatment-emergent AEs if they have a star t date on or after the administration of study 
intervention during the treatment period. Freque ncy and percentages by [CONTACT_800733], SAEs, AEs of sp ecial interest, and AEs by [CONTACT_2073].  
Descriptive statistics and changes from baseline will be provided for vital signs, 12-lead ECG, 
clinical laboratory tests, and physical exa mination findings by [CONTACT_6982]. 
Laboratory parameter shifts from baseline to abnormal post-baseline values will be presented by [CONTACT_1570]. Mean laboratory values over time will be plotted by [CONTACT_7169]. 
By-participant listings will be provided for all the safety parameters. 
9.4.3.  Secondary Endpoints 
PD analyses will be performed on the Pharmaco dynamic Population, and PK analyses will be 
performed on Pharmacokinetic Population. Actual sampling times will be used for all parameter 
estimations. The principal secondary endpoint of in terest will be the cha nge from baseline in the 
composite 6-symptom score after EIAs (as described in Section [IP_ADDRESS] ).  
[IP_ADDRESS].  EIA Composite Score 
EIAs will include an active assessment of the 6 key symptoms (flushing, headache, palpi[INVESTIGATOR_814], 
lightheadedness, nausea, and vomiti ng) that DCR-AUD may elicit, in  order to determine if the 
protocol-specified DCR-AUD dose regimen gives the proper constellation of these symptoms. 
These symptoms will be collected by [CONTACT_800734].  
The following symptom scoring framework would be  described as an arbitrary point system, 
where: 
Symptom  No Symptom Mild symptom Moderate symptom Severe symptom 
Score  [ADDRESS_1105299] non-missing value prior to alcohol administration. 
Descriptive statistics of EIA composite score (n, mean, median, IQR [Inter Quartile Range], 
minimum and maximum) for absolute values and changes from baseline will be presented by [CONTACT_3148], placebo, vis it, and time point.  
Descriptive statistics of Peak EIA composite  score (n, mean, medi an, IQR, minimum and 
maximum) for absolute values and changes from baseline will be presented by [CONTACT_3148], 
placebo, and visit (Days). The Peak EIA compos ite score is defined as maximum composite 
score at each visit. 
Dicerna Protocol DCR-AUD-102 Version 2.0, 17-Jan-2023 
 Page 53 [IP_ADDRESS].  Blood Biomarkers 
Descriptive statistics and cha nge from baseline will be provi ded for blood PD assessments, 
including acetaldehyde accumulation (absolute values and AUC) during the EIAs, where 
applicable.  
[IP_ADDRESS].  Pharmacokinetics 
Plasma concentrations and PK  parameters will be listed a nd summarized by [CONTACT_48007]. The arithme tic mean, SD, CV%, geom etric mean, geometric 
CV%, minimum, median, and maximum will be presented.  
Additional PK parameters may be estimated if deemed appropriate. Details will be provided in 
the PK Analysis Plan. Analysis of PK parameters may be reported in a supplement to the CSR.  
PK analyses will be conducte d with noncompartmental and/or  compartmental models to 
determine PK paramete r estimates. Population PK and P opulation PK-PD analyses may be 
performed and will be reported in a separate report. 
9.4.4.  Exploratory Endpoint(s) 
The exploratory endpoint of change in drinki ng amounts will be assessed using the TLFB and by 
[CONTACT_800735].  
Average daily drinking amounts over each 2-week  period after the start of dosing will be 
compared to the amount during the 2-week period  before first dose. Change in drinking amounts 
for each postdose period will be evaluated in connection with changes in EIA-induced peak 
symptoms and plasma acetaldehyde levels during the preceding EIA. 
Other exploratory analyses will be conducted as deemed appropria te and will be detailed in the 
SAP.  
9.5. Interim Analysis 
In order to enable decision making for the future  clinical development of DCR-AUD, an interim 
analysis may be conducted after all participants have received a ll 3 doses of study intervention.  
Variables to be analyzed may include assessmen ts of safety (AEs, la boratory testing, physical 
findings), pharmacokinetics, and pharmacodynamics  (blood biomarkers and physiologic signs 
and symptoms). Should the interim analysis be conducted, complete details  will be provided in 
the SAP. 
9.6. Safety Review Commi ttee and Data Safety Monitoring Committee 
An SRC will conduct periodic revi ews and will review all cumula tive safety, tolerability, and 
available PD data on participan ts. Participant safety  will be continuously monitored by [CONTACT_800736], laboratory results, and ot her protocol-specified assessments, to allow 
safety signal detecti on throughout the study.  
Table [ADDRESS_1105300] to the po ssible occurrence of study stoppi[INVESTIGATOR_004] (see 
Section 7.4 ).  
Dicerna Protocol DCR-AUD-[ADDRESS_1105301] opped to ensure the safety of study 
participants. 
Complete details on the res ponsibilities of the Safety Committ ees will be detailed in the 
committee charters. For additional details on the composition of the SRC and DSMC, refer to 
Section 10.1.5 . 
 
Dicerna Protocol DCR-AUD-102 Version 2.0, 17-Jan-2023 
 Page 55 Table 5: Minimal Timing of the Sa fety Review Committee Data Reviews  
Occurrence of a 
significant or severe 
adverse symptom Upon the occurrence of a significant or severe adverse symptom (see Section 7.3 ), 
all dosing and enrollment into the study will be interrupted until safety data can be 
reviewed by [CONTACT_12217]. The SRC will review the events associated with the 
significant or severe adverse symptom as well as the cumulative safety data collected on all participants previously dosed. The SRC will determine whether 
dosing, enrollment, and subsequent EIAs may resume. 
Occurrence of a safety 
issue that, in the SRC‚Äôs clinical judgment, could 
affect participant safety 
or study conduct  Upon the occurrence of a situation or safety question that could affect participant 
safety or study conduct, the SRC will meet to discuss the issue. Actions to be taken include, but are not limited to: 
x Discontinuation of an individual participant 
x Discontinuation of dosing  
x Discontinuation of additional EIAs 
x Referral to the DSMC for review and recommendation, should a pattern of 
AEs of concern be identified, regardless of severity 
Occurrence of a potential study stoppi[INVESTIGATOR_800701] a potential study stoppi[INVESTIGATOR_1877] (see Section 7.4
), all dosing 
and enrollment will be interrupted until safety data can be reviewed by [CONTACT_12217]. 
The SRC will review the events  associated with the trigge ring of the stoppi[INVESTIGATOR_800702]. The SRC will determine whether dosing and enrollment may resume. The SRC may 
elect to refer the issue that triggered the study interruption to the DSMC for an 
independent review and recommendatio n regarding study resumption.  
Abbreviations: AE: adverse event; AUD: alcohol use disorder ; DSMC: Data Safety Monitori ng Committee; EIA: ethanol 
interaction assessment; SRC: Safety Review Committee  
 
Dicerna Protocol DCR-AUD-102 Version 2.0, 17-Jan-2023 
 Page 56 10. SUPPORTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS 
10.1. Regulatory, Ethical, and Study Oversight Considerations 
10.1.1.  Regulatory and Ethical Considerations 
This study will be conducted in accordance with  the protocol and with the following:  
x Consensus ethical principles  derived from international guidelines, including the 
Declaration of Helsinki and Council for International Organizations of Medical 
Sciences (CIOMS) International Ethical Guidelines  
x Applicable ICH Good Clinical Practice (GCP) Guidelines  
x Applicable laws and regulations  
The protocol, protocol amendments, ICF, Invest igator Brochure, and ot her relevant documents 
(e.g., advertisements) must be submitted to an IRB/IEC by [CONTACT_78792]/IEC befo re the study is initiated.  
Any amendments to the protocol will require IRB/IEC approval before implementation of 
changes made to the study design, except for changes necessary to eliminate an immediate 
hazard to study participants.  
The Investigator will be responsible for the following:  
x Providing written summaries of the status of  the study to the IRB/IEC annually or 
more frequently in accordance with the requirements, policies, and procedures 
established by [CONTACT_1201]/IEC  
x Notifying the IRB/IEC of SAEs or other si gnificant safety findings as required by 
[CONTACT_1744]/IEC procedures 
x Providing oversight of the conduct of th e study at the site and adherence to 
requirements of 21 CFR, ICH guidelines, the IRB/IEC, European regulation 536/2014 
for clinical studies (if applicable), a nd all other applicable local regulations 
10.1.2.  Financial Disclosure 
Investigators and sub-Investigators will provide the Sponsor with sufficient, accurate financial 
information as requested to allow the Sponsor  to submit complete and accurate financial 
certification or disclosure statements to the appropriate regulatory authorities. Investigators are 
responsible for providing informa tion on financial intere sts during the course of the study and for 
1 year after completion of the study. 
10.1.3.  Informed Consent Process 
Each interested prospective participant (or legally authorized representative) will receive an 
informed consent document that contains study in formation and be given ample time to read the 
information and consider particip ation. The Investigator or his/he r representative will explain the 
nature of the study and its risks and potential benefits to the pros pective participant or his/her 
legally authorized representative and an swer all questions regarding the study. 
Dicerna Protocol DCR-AUD-[ADDRESS_1105302] (HIPAA) requirements, where applicable, 
and the IRB/IEC or study center.  
The medical record must include a statement that written informed consent was obtained before 
the participant was enrolled in the study, and the date the written consent was obtained. The 
authorized person obtaining the informed consent must also sign the ICF.  
Participants must be re-consented to the most  current version of the ICF(s) during their 
participation in the study.  
A copy of the ICF(s) must be provided to the part icipant or the participan t‚Äôs legally authorized 
representative. 
10.1.4.  Data Protection 
Participants will be a ssigned a unique identifier by [CONTACT_941] S ponsor. Any participant records or 
datasets that are transferred to the Sponsor will contain the identifier only;  participant names or 
any information which would make the participant identifiable will not be transferred.  
The participant must be informed that his/her personal study-related data will be used by [CONTACT_19490]. The level of disclosure must also be 
explained to the participants, who will be required to give consent for their data to be used as 
described in the informed consent  
The participant must be informed that his/her medical records may be examined by [CONTACT_800737], by 
[CONTACT_6667]/IEC members, and by [CONTACT_6668]. 
10.1.5.  Committees Structure 
[IP_ADDRESS].  Safety Review Committee 
The SRC will comprise the PI [INVESTIGATOR_1238]/or sub-Inves tigator, the Sponsor Medical Monitor, and the 
CRO Medical Monitor.  
See Section 9.5  for further details regarding the SRC. 
[IP_ADDRESS].  Data Safety Monitoring Committee 
The independent DSMC will compri se appropriately qualif ied clinicians who are not involved in 
the study. The DSMC will provide a comprehensive review of study safety and tolerability data 
on an ad hoc basis. Further operational details will be prespecified in the DSMC charter. 
Dicerna Protocol DCR-AUD-[ADDRESS_1105303] all medical data during 
this trial. ClinBase‚Ñ¢ is a software tool designed similarly to an electronic medical record for the 
documentation of e.g., medical hi story, demographics, vital signs, and AEs. Unlike a system 
(which is relying on data from other sources like pa per records and is setup just to digitize these 
data for transmission), ClinBase ensures quality assurance and enables comprehensive capture of 
all relevant medical in formation gathered during clinical  studies. Through a system provided 
workflow that includes barcode scanning and inte rfaces to medical equipm ent, trial operations 
performance is controlled and captured in real time. Thus, the system provides 100% 
transparency for monitors and is at any time accessible to the Investigators and clinical personnel for all medical docume ntation processes. 
ClinBase meets ICH GCP requirements as data  are attributable, legi ble, contemporaneous, 
original, accurate, and complete (ALCOA-C). The system is fully Code of Federal Regulations (CFR) Title 21 Part 11 compliant. 
The Investigator will ensure the accuracy, completeness and timeliness of the data reported to the 
Sponsor. System supported data collection proces ses and procedures are validated to ensure 
completeness, accuracy, reliability, and consistency. A complete audit trail is maintained of all 
data changes. The Investigator or designee will cooperate with the Sponsor‚Äôs representative(s) 
for the periodic review of trial documents to en sure the accuracy and completeness of the data 
capture system at each scheduled monitoring visit. 
Electronic consistency checks (plausibility and completeness) will be used along with the 
Investigator review to identify any errors or inconsistencies in the data. Data clarification 
requests will be provided to the trial team by [CONTACT_25317]. 
During the trial setup, adequate and accurate c linical procedure forms are used to generate 
medical records, digital ECGs, AE and conco mitant medication reporti ng, raw data collection 
forms, etc., which are designed as protocol to r ecord all observations and other pertinent data for 
each subject receiving trial medication. The only regul arly used paper-based trial document is the 
ICF because it requires wet-ink signatures. The ICFs will be archived in paper form at the end of the trial. Should additional paper forms be used, the recorded data must be transferred into 
ClinBase accurately and within due time. In pre-stabilized intervals or at the end of the trial, data 
will be exported from ClinBa se data management syst ems for further processing. 
The Investigator will allow Spons or representatives, contract de signees, authorized regulatory 
authority inspectors and the IRB to have direct access to all electronic records pertaining to the 
trial. 
All data should be recorded, ha ndled, and stored in a way that  allows its accurate reporting, 
interpretation, and verification. 
Dicerna Protocol DCR-AUD-102 Version 2.0, 17-Jan-2023 
 Page 59 Monitoring details describing stra tegy (e.g., risk-based initiatives in operations and quality such 
as Risk Management and Mitiga tion Strategies and Analytical Risk-Based Monitoring), methods, 
responsibilities, and requirements , including handling of noncompliance issues and monitoring 
techniques (central, remote, or  on-site monitoring) are provided in the Monitoring Plan. 
The Sponsor or designee is responsible for the data management of th is study, including quality 
checking of the data.  
The Sponsor assumes accountability for actions delegated to other i ndividuals (e.g., CROs).  
Study monitors will perform ongoing source data veri fication to confirm that  data entered into 
the eCRF by [CONTACT_165577] a ccurate, complete, and verifiable from source 
documents; that the safety and ri ghts of participants are being pr otected; and that the study is 
being conducted in accordance with the curr ently approved protocol and any other study 
agreements, ICH GCP, and all app licable regulatory requirements.  
Records and documents, including signed ICFs, pe rtaining to the conduct of this study must be 
retained by [CONTACT_13177] [ADDRESS_1105304] been collected and a study-site closure visit has been performed.  
The Investigator may initiate study-site closure at any time, pr ovided there is reasonable cause 
and sufficient notice is given in a dvance of the intended termination.  
Reasons for the early closure of a study site by [CONTACT_3433] e Sponsor or Investigator may include but are 
not limited to:  
x Investigator noncompliance with the prot ocol, GCP, or regulatory requirements  
x Unsatisfactory enrollment with respect to quantity or quality  
x Incomplete data collection; inaccurate  or knowingly false data submission  
x The PI [INVESTIGATOR_800703] e tasks of the PI, and no replacement can 
be found.  
x The SRC determines that ter mination of the study is in the best interest of the 
research participants. 
x The Sponsor, Investigator or IRB/IEC dete rmines that continuation of the study will 
not serve any scientific purpose.  
Dicerna Protocol DCR-AUD-102 Version 2.0, 17-Jan-2023 
 Page 60 x Circumstances beyond the control of th e Sponsor or Investigator make it 
unreasonable to require the study‚Äôs continuation. 
x A request to discontinue the study by a regulatory or health authority.  
If the study is prematurely terminated or susp ended, the Sponsor shall promptly inform the 
Investigators, the IECs/IRBs, the regulatory auth orities, and any CRO(s) used in the study of the 
reason for termination or suspension, as specified  by [CONTACT_1214]. The 
Investigator shall promptly info rm the participants and should assure appropriate participant 
therapy and/or follow-up. The complete set of stoppi[INVESTIGATOR_1877] s is detailed in Section [ADDRESS_1105305].  
Note: Any language relati ng to these issues appearing in the clinical study agreement will 
supersede that which is outlined in this section. 
10.2. Clinical Laboratory Tests 
Table [ADDRESS_1105306] document their review  of each laboratory safety report.  
Laboratory/analyte results that could unblind the study will not be reported to inve stigative sites 
or other blinded personnel un til the study has been unblinded. 
 
  
Dicerna Protocol DCR-AUD-102 Version 2.0, 17-Jan-2023 
 Page 62 10.3. Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow-up, and Reporting 
10.3.1.  Definition of Adverse Event 
An AE is any untoward medical occurrence in a pa tient or clinical study pa rticipant, temporally 
associated with the use of study intervention, wh ether or not considered related to the study 
intervention. An AE can therefore be any unf avorable and unintended sign (including an 
abnormal laboratory finding), sympto m, or disease (new or exacer bated) temporally associated 
with the use of study intervention.  
Events Meeting the AE Definition  
x Any abnormal laboratory test re sults (hematology, clinical ch emistry, or urinalysis) or 
other safety assessments (e .g., ECG, radiological scans, vital signs measurements), 
including those that worsen from baseline, c onsidered clinically significant in the 
medical and scientific judgm ent of the Investigator.  
x Exacerbation of a chronic or intermittent pre-existing condition, including either an 
increase in frequency and/or intensity of the condition.  
x New condition detected or diagnosed afte r study intervention administration, even 
though it may have been present before the start of the study.  
x Signs, symptoms, or the clinical sequelae of a suspected drug-drug interaction.  
x Signs, symptoms, or the clinical sequelae of a suspected overdose of either study 
intervention or a concomitant medication. Over dose per se will not be reported as an 
AE/SAE unless it is an intentional overdose taken with possible suicidal/self-harming intent. Such overdoses should be reported regardless of sequelae.  
Events NOT Meeting the AE Definition  
x During the conduct of EIAs, par ticipants will be questioned by [CONTACT_800717] 
6 symptoms (flushing, headache, lightheade dness, palpi[INVESTIGATOR_814], na usea, and vomiting) 
associated with increased blood acetaldehyde levels. These symptoms solicited via active questioning do not meet the AE definition. 
x Medical or surgical procedure (e.g., e ndoscopy, appendectomy): the condition that 
leads to the procedure is the AE.  
x Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospi[INVESTIGATOR_307]).  
x Anticipated day-to-day fluctuations of pre- existing disease(s) or condition(s) present 
or detected at the start of the study that do not worsen.  
10.3.2.  Definition of Serious Adverse Event  
If an event is not an AE per definition above, then  it cannot be an SAE even if serious conditions 
are met. 
Dicerna Protocol DCR-AUD-[ADDRESS_1105307] me dical occurrence that, at any dose:   
x Results in death  
x Is life-threatening  
The term ‚Äòlife-threatening‚Äô in the definition of ‚Äòserious‚Äô refers to an event in which the 
participant was at risk of death at the time of the event. It does not refer to an event that 
hypothetically might have caused d eath if it were more severe.  
x Requires inpatient hospi[INVESTIGATOR_800704], hospi[INVESTIGATOR_800705] (usually involving 
at least an overnight stay) at the hospi[INVESTIGATOR_740387]/or treatment 
that would not have been a ppropriate in the physician‚Äôs office or outpatient setting. 
Complications that occur during hospi[INVESTIGATOR_325716]. If a complication prolongs 
hospi[INVESTIGATOR_306894] r serious criteria, the event is  serious. When in doubt as to 
whether ‚Äúhospi[INVESTIGATOR_059]‚Äù occurred or was neces sary, the AE should be considered serious.  
Hospi[INVESTIGATOR_5187] a pre-existing condition that did not worsen from 
baseline is not considered an AE. Pre-planned hospi[INVESTIGATOR_47952], for an elective medical/surgical pr ocedure do not meet this criterion.  
x Results in persistent disability/incapacity  
The term disability means a substantial disrup tion of a person‚Äôs ability  to conduct normal life 
functions.  
This definition is not intended to include expe riences of relatively mi nor medical significance 
such as uncomplicated headache, nausea, vomiti ng, diarrhea, influenza, and accidental trauma 
(e.g., sprained ankle), which may interfere with or prevent everyday life functions but do not 
constitute a substantial disruption.  
x Is a congenital anomaly/birth defect  
x Other situations:  
Medical or scientific judgment should be ex ercised in deciding whether SAE reporting is 
appropriate in other situations, such as important medical events that may not be immediately life-threatening or result in death or hospi[INVESTIGATOR_800706]. These events should usually be considered serious.  
Examples of such events include invasive or  malignant cancers, intensive treatment in an 
emergency room or at home for allergic br onchospasm, blood dyscrasias or convulsions that 
do not result in hospi[INVESTIGATOR_28689], or development of drug de pendency or drug abuse. 
10.3.3.  Definition of Adverse Events of Special Interest 
Per the Council for International Organiza tions of Medical Sciences Cumulative 
Pharmacovigilance Glossary ( CIOMS VI, 2021 ), an AESI (serious or non-serious) is one of 
scientific and medi cal concern specific to the Sponso r‚Äôs product or program, for which ongoing 
monitoring and rapid communication by [CONTACT_800738]. 
Such events may require further investigation in  order to characterize and understand them.  
Dicerna Protocol DCR-AUD-102 Version 2.0, 17-Jan-2023 
 Page 64 Events Meeting the AESI Definition  
Injection Site Reaction  
An ISR is characterized by [CONTACT_48016] (usually immunologic) developi[INVESTIGATOR_800707] [ADDRESS_1105308]-injection. Subcutan eous administration of the study 
intervention may cause a specific local reaction originating around the injection site, such as 
erythema, itching, discomfort and pain, and could include more se vere manifestations such as 
ulceration or necrosis.  
Potential ISRs will be evaluated and recorded as follows:  
Individual signs or symptoms at the injection site with an onset of less than 4 hours from the time 
of study intervention administration will be r ecorded as individual AEs (bruising, itching, 
transient erythema, swelling, etc.) and not as ISRs.  
Signs or symptoms at the injection site with a time to onset of [ADDRESS_1105309]-injection will 
be recorded as an ISR if any of the CTCAE criteria for ISR detailed in Table 7  are met. Signs or 
V\PSWRPVDWWKHLQMHFWLRQVLWHWKDWRFFXU¬ïKRXUVSRVW -injection but are not specified in Table 7  
should be recorded as AEs. 
Table 7: Grading of Injectio n Site Reactions, CTCAE v 5.0 
Grade 1 Grade 2 Grade 3 Grade 4 Grade 5 
Tenderness with 
or without associated 
symptoms (e.g., 
warmth, erythema, itching) Pain, 
lipodystrophy; edema; phlebitis Ulceration or 
necrosis; severe tissue damage; 
operative 
intervention indicated Life-threatening 
consequences; urgent 
intervention 
indicated Death 
 
10.3.4.  Recording and Follow-up of AEs and/or SAEs 
[IP_ADDRESS].  AE and SAE Recording 
When an AE/SAE occurs, it is the responsibility of  the Investigator to review all documentation 
(e.g., hospi[INVESTIGATOR_1088], la boratory reports, diagnostics repor ts) related to the event.  
The Investigator will then record all relevant AE/SAE information in the eCRF.  
It is not acceptable for the Investigator to send ph otocopi[INVESTIGATOR_10914]'s medical records to 
the Sponsor in lieu of completi on of the AE/SAE CRF page.  
There may be instances when copi[INVESTIGATOR_800708]. In this case, all partic ipant identifiers, with the excepti on of the participant number, will 
be redacted on the copi[INVESTIGATOR_47957].  
The Investigator will attempt to establish a di agnosis of the event based on signs, symptoms, 
and/or other clinical information. Whenever possible, the diagnosis (not the individual 
signs/symptoms) will be documented as the AE/SAE. 
Dicerna Protocol DCR-AUD-102 Version 2.0, 17-Jan-2023 
 Page 65 [IP_ADDRESS].  Assessment of Intensity 
The Investigator will make an assessment of each AE and SAE reported during the study. The 
grade of each event will be dete rmined using CTCAE v 5.0 criteria. 
[IP_ADDRESS].  Assessment of Causality 
The Investigator is obligated to assess the relationship between study intervention and each 
occurrence of each AE/SAE.  
A ‚Äúreasonable possibility‚Äù of a relationship conve ys that there are facts, evidence, and/or 
arguments to suggest a causal relationship, rath er than a relationship cannot be ruled out.  
The Investigator will use clinical judgment to determine the relationshi p. Alternative causes, 
such as concomitant therapy and other risk factors, as well as the temporal relationship of the 
event to study intervention administration will be considered and investigated. The Investigator 
will also consult the Investigator Brochure (I B) and/or Product Information (for marketed 
products) in his/her assessment.  
For each AE/SAE, the Investigator must document in the medical notes that he/she has reviewed 
the AE/SAE and has provided an assessment of causality.  
There may be situations in which an SAE has occurred, and the I nvestigator has minimal 
information to include in the initial report. However, it is very important that the Investigator always make an assessment of causality for every event before the initial transmission of the SAE data to SAE Coordinator.  
The Investigator may change his/her opi[INVESTIGATOR_9242]-up information and 
send a SAE follow-up report with th e updated causality assessment.  
The causality assessment is one of the criteria used when determining regulatory reporting 
requirements.  
The following definitions will be used in assessing causality:  
x Not Related: Event for which sufficient evidence ex ists to conclude that the etiology 
is unrelated to study intervention.  
x Possibly Related: There is some temporal relationship between the event and the 
administration of the study intervention, and the event is unlikely to be explained by 
[CONTACT_2299]‚Äôs medical cond ition or other therapi[INVESTIGATOR_014].  
x Probably Related:  The temporal relationship between the event and administration 
of the study intervention is suggestive a nd the event is unlikely explained by [CONTACT_2416]‚Äôs medical condition or other therapi[INVESTIGATOR_014]. 
x Definitely Related:  The event follows reasonabl e temporal sequence from 
administration of the study intervention, follows a known or suspected response 
pattern to the study intervention, is confirmed by [CONTACT_800739][INVESTIGATOR_47959], and reappears upon repe ated exposure, if that occurs. 
Dicerna Protocol DCR-AUD-102 Version 2.0, 17-Jan-2023 
 Page 66 [IP_ADDRESS].  Follow-up of AEs and SAEs 
The Investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations  as medically indicated or as  requested by [CONTACT_208050]/or causality of the AE or SAE as fully as possible. This may include additional laboratory tests or investigations, histopathological examinations, or consultation with 
other health care professionals.  
If a participant dies during par ticipation in the study or during a recognized follow-up period, the 
Investigator will provide the Sponsor with a copy of any post-mortem findings including 
histopathology.  
New or updated information will be recorded in the originally completed CRF.  
The Investigator will submit any updated SAE data to the Sponsor within [ADDRESS_1105310] ion of Pregnancy Information  
10.4.1.  Definitions  
Woman of Childbearing Potential (WOCBP)  
A woman is considered fertile following mena rche and until becoming post-menopausal unless 
permanently sterile (see below).  
If fertility is unclear (e.g., amenorrhea in athletes) and a menstrual cycle cannot be confirmed 
before administration of study intervention, a dditional evaluation should be considered.  
Women in the following categories are not considered WOCBP  
1. Premenarchal  
2. Premenopausal with one of the following:  
a. Documented hysterectomy  
b. Documented bilateral salpi[INVESTIGATOR_1656]  
c. Documented bilateral oophorectomy  
Dicerna Protocol DCR-AUD-102 Version 2.0, 17-Jan-2023 
 Page 67 For individuals with permanent infertility due to an alternate medical cause other than the 
above, (e.g., m√ºllerian agenesis, androgen inse nsitivity), Investigator discretion should be 
applied to deter mining study entry.  
Note: Documentation can come from the site personnel‚Äôs: review of the participant‚Äôs 
medical records, medical examinati on, or medical history interview.  
3. Postmenopausal  
a. A postmenopausal state is defined as no menses for 12 months without an 
alternative medical cause.  
A high follicle stimulating hormone (FSH ) level in the postmenopausal range 
may be used to confirm a postmenopausal state in women not using hormonal 
contraception or hormonal replacemen t therapy (HRT). However, in the 
absence of [ADDRESS_1105311] discontinue HRT to allow confirmation of pos tmenopausal status before 
study enrollment. 
10.4.2.  Contraception Guidance 
Male Participants 
Male participants with female partners of childbearing potential are eligible to participate if they 
agree to ONE of the following from Day 1 through the end of study (EOS) visit:  
x Are abstinent from penile-vaginal intercour se as their usual and preferred lifestyle 
(abstinent on a long-term and persistent ba sis) and agree to remain abstinent. 
x Agree to use a male condom plus partner us e of a contraceptive method with a failure 
rate of < 1% per year as described in Table [ADDRESS_1105312] agree to remain abstinent from 
penile-vaginal intercourse or use a male c ondom during each epi[INVESTIGATOR_800709]-defined time frame.  
Female Participants  
Female participants of childbearing potential are eligible to participate if they agree to use a 
highly effective method of contraception cons istently and correctly as described in Table 8.  
Dicerna Protocol DCR-AUD-102 Version 2.0, 17-Jan-2023 
 Page 68 Table 8: Highly Effective Contraceptive Methods 
Highly Effective Contraceptive Methods That Are User Dependent a 
(Failure rate of <1% per year when used consistently and correctly) 
Combined (estrogen- and progestogen-containing) hormonal contraception associated with inhibition 
of ovulation  
x Oral  
x Intravaginal  
x Transdermal  
Progestogen-only hormonal contraception a ssociated with inhibition of ovulation 
x Oral  
x Injectable  
Sexual abstinence  
Sexual abstinence is considered a highly effective method only if defined as refraining from 
heterosexual intercourse during the entire period of risk associated with the study intervention. 
The reliability of sexual abstinence needs to be evaluated in relation to the duration of the study and the preferred and usual lifestyle of the participant. 
Highly Effective Methods That Are User Independent a 
x Implantable progestogen-only hormonal contraception associated with inhibition of 
ovulation  
x Intrauterine device (IUD) 
x Intrauterine hormone-releasing system (IUS) 
x Bilateral tubal occlusion 
x Vasectomized partner  
A vasectomized partner is a highly effective contraception method provided that the partner is 
the sole male sexual partner of the WOCBP, and the absence of sperm has been confirmed. If 
not, an additional highly effective method of contraception should be used.  
10.4.3.  Collection of Pregnancy Information 
[IP_ADDRESS].  Male Participants with Partners Who Become Pregnant 
The Investigator will attempt to collect pregnancy information on any male participant‚Äôs female 
partner who becomes pregnant while  the male participant is in this study. This applies only to 
male participants who receive DCR-AUD.  
After obtaining the necessary signe d informed consent from the preg nant female partner directly, 
the Investigator will record pregnancy information on the appropriate form and submit it to the 
Sponsor within 24 hours of learning of the partne r‚Äôs pregnancy. The female  partner will also be 
followed to determine the outcome of the pregnanc y. Information on the status of the mother and 
Dicerna Protocol DCR-AUD-102 Version 2.0, 17-Jan-2023 
 Page 69 child will be forwarded to the Sponsor. Genera lly, the follow-up will be no longer than 6 to 10 
weeks following the estimated delivery date. Any termination of the pregnancy will be reported 
regardless of fetal status (presence or absence of anomalies) or indica tion for the procedure. 
[IP_ADDRESS].  Participants Who Become Pregnant 
The Investigator will collect pregnancy information on any participant who becomes pregnant 
while participating in this study. The initial Information will be r ecorded on the appropriate form 
and submitted to the Sponsor within 24 hours of  learning of a partic ipant‚Äôs pregnancy.  
The participant will be followed to determine the outcome of the pregnancy. The Investigator 
will collect follow-up information on the participant and the neonate, and the information will be 
forwarded to the Sponsor. Generally, follow-up will not be required for longer than 6 to 
10 weeks beyond the estimated delivery date. Any termination of pregna ncy will be reported, 
regardless of fetal status (presence or absence of  anomalies) or indicati on for the procedure.  
While pregnancy itself is not cons idered to be an AE or SAE,  any pregnancy complication or 
elective termination of a pregnancy for medical reasons will be reported as an AE or SAE. A 
spontaneous abortion (occurring at < 22 weeks ge stational age) or still birth (occurring at 
> 22 weeks gestational age) is always considered to be an SAE and will be reported as such. Any post-study pregnancy-related SAE c onsidered reasonably related to the study intervention by [CONTACT_800740] 8.3.4. While the Investigator 
is not obligated to actively seek this information in former study participants, he or she may learn 
of an SAE through spontaneous reporting.  
Any participant who becomes pre gnant while participating in the study will discontinue study 
intervention. 
10.5. Genetics 
Use/Analysis of DNA  
x DNA samples will be analyzed for ALDH2  genotypi[INVESTIGATOR_007]. Additional exploratory 
analyses may be conducted if it is hypothesized  that this may help further understand 
the clinical data.  
x The results of genetic analyses may be re ported in the CSR or in a separate study 
summary.  
x The Sponsor will store the DNA samples in a secure storage space with adequate 
measures to protect confidentiality.  
x The samples will be retain ed while research on DCR-AUD continues, but no longer 
than 5 years or other period as per local requirements. 
Dicerna Protocol DCR-AUD-102 Version 2.0, 17-Jan-2023 
 Page 70 10.6. Liver Safety: Suggested Action s and Follow-up Assessments 
Phase 1 liver chemistry stoppi[INVESTIGATOR_800710]: 
Liver Chemistry Stoppi[INVESTIGATOR_2121]  
(Applies both to additional DCR-AUD dosing and further EIAs) 
ALT/AST-
absolute ALT or AST increases to ¬ï√óULN 
,I$/7RU$67¬ï increases to >2 √óULN AND  total bilirubin t 2√óULN (> 35% 
direct bilirubin) or INR > 1.5, report to Sponsor in expedited manner.a, b 
See additional actions and follow-up assessments below 
a Serum bilirubin fractionation should be performed if testin g is available. If serum bilirubin fractionation is not 
LPPHGLDWHO\DYDLODEOHGLVFRQWLQXHVWXG\LQWHUYHQWLRQLI$/7¬ï √ó8/1DQGWRWDOELOLUXELQ¬ï √óULN. 
Additionally, if serum bilirubin fractionation testing is unavailable, record the absence/presence of detectable urinary bilirubin on dipstick which is indicative of direct b ilirubin elevations suggesting liver injury.  
b $OOHYHQWVRI$/7¬ï √ó8/1DQGWRWDOELOLUXELQ¬ï  2√óULN (> GLUHFWELOLUXELQRU$/7¬ï √óULN and 
INR > 1.5 may indicate severe liver injury (possible ‚ÄòHy‚Äôs Law‚Äô) and must be reported to sponsor in an expedited 
manner and as an SAE if SAE criteria met (excluding studies of hepatic impairment or cirrhosis).  
 
Required Actions, Monitoring, and Follow-up Assessments  
Actions: 
x Immediately discontinue study intervention 
x Report the event to the CRO Medical Monitor within 24 hours  
x Complete an SAE data collection tool if the event also met the criteria for an SAE b 
x Perform liver function follow-up assessments as described in the Follow Up Assessments 
below.  
x Do not restart or rechallenge participant with study intervention (neither IMP nor additional 
EIAs). 
x Monitor the participant until liver function test abnormalities resolve, stabilize, or return to 
baseline (as detailed below).  
Monitoring: 
If ALT or AST ¬ï 3√óULN AND total bilirubin tt2√óULN or INR > 1.5 
x Repeat liver function tests (include ALT, AST, alkaline phosphatase, total bilirubin, and INR) 
and perform liver function follow-up assessments within [ADDRESS_1105313] ¬ï 3√óULN AND total bilirubin < 2√ó 8/1DQG,15¬î  1.5: 
x Perform liver function tests (include ALT, AST, alkaline phosphatase, total bilirubin, and INR) 
and perform liver function follow-up assessments within 24 to 72 hours  
x Monitor participants weekly until liver function abnormalities resolve, stabilize, or return to 
baseline 
Dicerna Protocol DCR-AUD-102 Version 2.0, 17-Jan-2023 
 Page 71 Follow-Up Assessments:  
x Viral hepatitis serology (includes Hepatitis A IgM antibody; HBsAg and HBcAb; hepatitis C 
RNA; cytomegalovirus IgM antibody; Epstein-Barr viral capsid antigen IgM antibody [or if 
unavailable, heterophile antibody or monospot testing]; and hepatitis E IgM antibody)  
x Obtain serum CK, LDH, GGT, GLDH, and serum albumin 
x Fractionate bilirubin, if total bilirubin t 2√óULN 
x Obtain complete blood count with differential to assess eosinophilia 
x Record the appearance or worsening of clinical symptoms of liver injury, or hypersensitivity, 
on the eCRF 
x Record use of concomitant medications or ingestions (including wild mushrooms, 
acetaminophen, herbal remedies, recreational drugs, and other over-the-counter medications). 
Note any concomitant medications that have been recently initiated or for which doses have increased. 
x Record alcohol use on the eCRF 
 
If ALT or AST ¬ï 3√óULN AND total bilirubin t
t2√óULN or INR > 1.5 obtain the following in 
addition to the assessments listed above : 
x Anti-nuclear antibody, anti-smooth muscle antibody, Type 1 anti-liver kidney microsomal 
antibodies, and quantitative total immunoglobulin G (IgG) or gamma globulins 
x Liver imaging (ultrasound, magnetic resonance, or computerized tomography) and/or liver 
biopsy to evaluate liver disease  
x Liver biopsy may be considered and discussed with local specialists if available, for instance: 
 When serology raises the possibility of autoimmune hepatitis (AIH) 
 When suspected DILI progresses or fails to resolve on withdrawal of study intervention 
 In participants with acute or chronic atypi[INVESTIGATOR_31790]. 
 
 
Dicerna Protocol DCR-AUD-102 Version 2.0, 17-Jan-2023 
 Page 72 10.7. Abbreviations 
Abbreviation Description 
ADA antidrug antibody(ies) 
AE adverse event 
AESI AE of special interest 
ALDH2 aldehyde dehydrogenase [ADDRESS_1105314] aspartate aminotransferase 
AUC area under the curve 
AUD alcohol use disorder 
BAC blood alcohol concentration 
BMI body mass index 
BP blood pressure 
bpm beats per minute 
BUN blood urea nitrogen 
¬∞C degrees Celsius 
CFR Code of Federal Regulations 
CFU conditional follow-up 
CIOMS Council for International Organizations of Medical Sciences 
CK creatine kinase (creatine phosphokinase) 
CL clearance 
Cmax maximum observed concentration 
Cmin minimum observed concentration 
CONSORT Consolidated Standards of Reporting Trials 
CRO contract research organization 
CSR clinical study report 
C-SSRS Columbia-Suicide Severity Rating Scale 
CTCAE Common Terminology Criteria for Adverse Events 
CV% coefficient of variation (percent) 
DCR-A1203 drug substance for this IMP 
Dicerna Protocol DCR-AUD-102 Version 2.0, 17-Jan-2023 
 Page 73 Abbreviation Description 
DS drug substance 
DSMC Data Safety Monitoring Committee 
ECG electrocardiogram 
eCRF electronic case report form 
e.g. for example ( exempli gratia ) 
EIA ethanol interaction assessment 
EOS end of study 
EOT end of treatment 
ETOH ethyl alcohol 
FDA Food and Drug Administration 
FIH first-in-human 
FSH follicle stimulating hormone 
GABA gamma-aminobutyric acid 
GalNAc N-acetylgalactosamine 
GCP Good Clinical Practice 
GGT gamma glutamyl transferase 
GI gastrointestinal 
GLP Good Laboratory Practice 
HbA1c hemoglobin A1c 
HBsAg hepatitis B surface antigen 
hCG human chorionic gonadotropin 
HCV hepatitis C virus 
HIPPA Health Insurance Portability and Accountability Act 
hr hour(s) 
HIV human immunodeficiency virus 
HRT hormone replacement therapy 
HV healthy volunteer 
IA interim analysis  
IB Investigator‚Äôs Brochure 
ICF informed consent form 
ICH The International Council for Harmonisation of Technical Requirements for 
Pharmaceuticals for Human Use 
Dicerna Protocol DCR-AUD-102 Version 2.0, 17-Jan-2023 
 Page 74 Abbreviation Description 
i.e. that is ( id est ) 
IEC Independent Ethics Committee 
IMP Investigational Medicinal Product  
INR international normalized ratio 
IRB Institutional Review Board 
ISR injection site reaction 
ITT Intent to treat 
IUD intrauterine device 
IVRS/IWRS Interactive Voice/Web Response System 
IUS intrauterine hormone-releasing system 
kg kilogram(s) 
LDH lactate dehydrogenase 
LFT liver function test 
MCH mean corpuscular hemoglobin 
MCHC mean corpuscular hemoglobin concentration 
MCV mean corpuscular volume 
mg milligram(s) 
min minute(s) 
MINI Mini International Neuropsychiatric Interview 
mL milliliter(s) 
mRNA messenger ribonucleic acid 
NOAEL no observed adverse effect level 
NPO nothing by [CONTACT_800741]-inflammatory drug 
OTC over the counter 
PD pharmacodynamic(s) 
PEth phosphatidylethanol 
PK pharmacokinetic 
PI [INVESTIGATOR_800711] (Fridericia correction) 
RNA ribonucleic acid 
RNAi RNA interference 
Dicerna Protocol DCR-AUD-[ADDRESS_1105315] deviation 
SIB suicidal ideation or behavior 
siRNA small interfering RNA 
SoA schedule of activities 
SRC Safety Review Committee 
SUD substance abuse disorder 
S[LOCATION_003]R suspected unexpected serious adverse reaction 
t1/[ADDRESS_1105316] infection 
Vd/F apparent volume of distribution 
WFI water for injection 
WOCBP woman(en) of childbearing potential 
Dicerna Protocol DCR-AUD-102 Version 2.0, 17-Jan-2023 
 Page 76 10.8. Protocol Amendment History 
Amendment 1 (17-Jan-2023) 
Overall Rationale for the Amendment 
The protocol was amended in response to que ries from the US Food and Drug Administration. 
Additional updates and clarifica tions were also included.  
The Protocol Amendment Summary of Changes Table  for the current amendment is located 
directly before the Table of Contents. 
 
Dicerna Protocol DCR-AUD-102 Version 2.0, 17-Jan-2023 
 Page 77 10.9. Investigator Signature [CONTACT_3490] 
 
A Phase 1b, Double-blind, Placebo-controlled, Repeat-dose, Safety, Tolerability, 
Pharmacokinetic, and Pharmacodynamic Study of DCR-AUD in Healthy Volunteers  
 Protocol Number:  DCR-AUD-102 
Version: 2.0 
Date:  17-Jan-[ADDRESS_1105317] this  trial in accordance with all stipulations of the 
protocol and in accordance with Good Clinical  Practice (GCP) guidelines, the Declaration of 
Helsinki, and local regulations (as applicable). 
  
Signature:  [CONTACT_1782]: 
Name:  [CONTACT_1641]: 
Institution:  Site Number: 
 
 
Dicerna Protocol DCR-AUD-[ADDRESS_1105318] E: An abnorm al phospholipid in rat organs after ethanol 
treatment. FEBS Lett 1983; 152: 24‚Äì8.  
Bae KY, Kim SW, Shin HY, Kim JM, Shin IS, Kim SJ, et al. The acute effects of ethanol and  
acetaldehyde on physiological res ponses after ethanol ingestion in young healthy men with 
different ALDH2 genotypes. Clin Tox. 2012 Apr 1;50(4):242-9. 
Bryson WC, McConnell J, Korthuis PT, McCarty D. Extended-release naltrexone for alcohol  
dependence: persistence and healthcare cost s and utilization. Am J Manag Care. 2011 Jun;[ADDRESS_1105319] 8:S222-34.  
Chick J, Gough K, Falkowski W, Kershaw P, Hore  B, Mehta B, et al. Disulfiram treatment of  
alcoholism. Br J Psychiatry. 1992 Jul;161:84-9.  
CIOMS Cumulative Pharmacovigilance Glo ssary, Geneva, Switz erland: Council for 
International Organizations of Me dical Sciences (CIOMS), 2021.   
EMA/CHMP/EWP/[ZIP_CODE]/2008 (previously EMEA/CHMP/EWP/[ZIP_CODE]/2008). Committee for 
Medicinal Products for Human Use (CHMP). Gu ideline on the development of medicinal 
products for the treatment of alc ohol dependence. 18 February 2010. 
Enomoto N, Takase S, Yasuhara M, Takada A. Acetaldehyde metabolism in different aldehyde  
dehydrogenase-2 genotypes. Alcohol Clin Exp Res. 1991;15(1):141-4. 
Gastfriend DR. A pharmaceutical industry pers pective on the economics of treatments for  
alcohol and opi[INVESTIGATOR_2537]. Ann NY Acad Sci. [ADDRESS_1105320];1327:112-30.  
Gnann H, Weinmann W, Thierauf A. Formati on of phosphatidylethanol and its subsequent 
elimination during an extensive drinking experiment over 5 days . Alcohol Clin Exp Res. 2012 
Sep;36(9):1507-11. 
Grant BF, Goldstein RB, Saha TD, Chou SP, Jung J, Zhang H, et al. Epi[INVESTIGATOR_47970]-5 
Alcohol Use Disorder: Results from the National Epi[INVESTIGATOR_800712]. JAMA Psychiatry. 2015 Aug;72(8):757-66. 
Han B, Hedden SL, Lipari R, C opello EA, Kroutil LA. Receipt of services for behavioral health  
problems: Results from the 2014 National Surv ey on Drug Use and Health. Rockville, MD: 
Substance Abuse and Mental Health Serv ices Administration. 2015 Sep. Available from: 
https://www.samhsa.gov/da ta/report/receipt-services-behavi oral-health-problems-results-2014-
national-survey-dr ug-use-and-health. 
Heier C, Xie H, Zimmermann R: Nonoxidativ e ethanol metabolism‚Äîfrom biomarkers to 
bioactive lipi[INVESTIGATOR_805]. Int Union Biochem Mol Biol 2016; 68:916‚Äì23.  
Javors 0$+LOO·Ä®.DSWXUF]DN15RDFKH-' .DUQV·Ä®:ULJKW7('RXJKHUW\'0 &KDUDFWHUL]DWLRQ
of the pharmacokinetics of phospha tidylethanol 16: 0/18: 1 and 16: 0/18: 2 in human whole 
blood after alcohol consumption in a clinical  laboratory study. Alcohol Clin Exp Res. 2016 
Jun;40(6):1228-34. 
Dicerna Protocol DCR-AUD-[ADDRESS_1105321];35(10):1749-58.  
Koppaka V, Thompson DC, Chen Y, Ellerma nn M, Nicolaou KC, Juvonen RO, et al. Aldehyde  
dehydrogenase inhibitors: a comp rehensive review of the pharmacology, mechanism of action, 
substrate specificity, and clinical application. Phar macol Rev. 2012 Jul;64(3):520-39. 
Knudsen HK, Abraham AJ, Roman PM. Adoptio n and implementation of medications in  
addiction treatment programs. J Addict Med. 2011 Mar;5(1):21-7.  
Kummer N, Ingels AS, Wille SM, Hanak C, Verbanck P, Lambert WE, et al. Quantification of 
phosphatidylethanol 18:0/18:1, 18:1/ 18:1, 16:0/16:0 in venous blood and venous and capi[INVESTIGATOR_800713]. Anal Bioanal 
Chem 2016; 408: 825‚Äì38. 
Litten RZ, Falk D, Ryan M, Fertig J. Resear ch opportunities for medications to treat alcohol  
dependence: addressing stakeholders‚Äô needs. Alcohol Clin Exp Res. 2014 Jan;38(1):27-32.  
Nishimura FT, Fukunaga T, Kajiura H, Umeno K,  Takakura H, Ono T, Nishijo H. Effects of 
aldehyde dehydrogenase-2 genotype  on cardiovascular and endocr ine responses to alcohol in 
young Japanese subjects. Au ton Neurosci. 2002;102:60-70. 
Peng G-S, Chen Y-C, Tsao T-P, Wang M-F, Yin S-J. Pharmacokine tic and pharmacodynamic 
basis for partial protection ag ainst alcoholism in Asians, heterozygous for the variant ALDH2*2  
gene allele. Pharmacogene t Genomics. 2007;17(10):845-55. 
Peng G-S, Wang M-F, Chen C-Y, Luu S-U, Chou  H-C, Li T-K, Yin S-J. Involvement of 
acetaldehyde for full protection against alcoho lism by [CONTACT_800742] e variant allele of  
mitochondrial aldehyde de hydrogenase gene in Asians. Pharmacogenetics. 1999;9:463-76. 
Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA, et al. The Columbia-
Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and a dults. Am J Psychiatry. 2011; 168(12):1266-77. 
Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini-
International Neuropsychiatric Interview (M.I .N.I.): the development and validation of a 
structured diagnostic psychiat ric interview for DSN-IV and ICD-10. J Clin Psychiatry. 1998;  
59[Suppl 20]:22-33.  
Sobell LC, Sobell MB. Timeline follow-back: A te chnique for assessing self-reported alcohol 
consumption. In: Litten RZ, Allen JP, editors. M easuring alcohol consump tion: psychosocial and  
biochemical methods. Washi ngton DC: American Psychol ogical Association.1992. pp. 41-72. 
Substance Abuse and Mental H ealth Services Administrati on, Results from the 2013 National 
Survey on Drug Use and Health: Summary of  National Findings, NSDUH Series H-48, HHS 
Publication No. (SMA) 14-4863. Roc kville, MD: Substance Abuse a nd Mental Health Services 
Administration, 2014. Available from: https ://www.samhsa.gov/data/s ites/default/files/
NSDUHresultsPDFWHTML2013/Web/NSDUHresults2013.pdf. 
Ulwelling W, Smith K. The PEth blood test in th e security environment: what it is; why it is 
important; and interp retative guidelines. J Forens ic Sci. 2018 Nov;63(6):1634-40. 
Dicerna Protocol DCR-AUD-102 Version 2.0, 17-Jan-2023 
 Page 80 Viel G, Boscolo-Berto R, Cecchetto G, Fais P, Nalesso A, Ferrara S: Phosphatidylethanol in 
blood as a marker of chronic alcohol use: a syst ematic review and meta-a nalysis. Int J Mol Sci 
2012; 13:[ZIP_CODE]‚Äì812.  
 